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Abstract

Lung cancer is the number one cause of cancer related death in both males and
females. About 20% of all non-small cell lung cancer (NSCLC) patients are expected to
harbor an epidermal growth factor receptor (EGFR) activating mutation. EGFR inhibitors
have been shown to provide clinical benefits over chemotherapy for lung cancer
patients with EGFR activating mutations. However, despite the initial clinical responses
to these EGFR targeted therapies, long-term efficacy is not possible because acquired
drug resistance hampers the effectiveness of these therapies. We found that a fiber
inspired smart scaffold (FiSS) platform established in our laboratory allows growth of
three-dimensional (3D) tumor-like aggregates (referred to as tumoroids), which
resemble in vivo tumors. Tumoroids exhibit better drug resistance compared to twodimensional (2D) cultures that lack ability to mimic the environment of the tumor
microenvironment. As the FiSS acts as a better representation of the in vivo tumor
environment, we have used the FiSS platform to help verify our most important
monolayer findings before proceeding to in vivo studies. We have developed EGFR
tyrosine kinase inhibitor (TKI) drug tolerant (DT) human lung cancer cell lines as model
for de novo drug resistance. The drug sensitivity of the parental and DT cells on both
the monolayer and the FiSS were determined by testing a panel of standard-of-care
chemotherapeutics along with EGFR TKIs. A comparison of the drug sensitivity showed
that parental cells were at least 2- fold more sensitive to the EGFR TKIs compared to
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the DT cells. Data mining the significantly differentially expressed proteins list generated
by the mass spectroscopic analysis revealed that the protein expression is skewed in
the EGFR TKI DT cell line as compared to the parental cell line. The cytochrome P450
protein CYP51A1, which is directly involved with cholesterol synthesis, was significantly
up-regulated in the DT cells compared to the parental cells. Western blotting has
confirmed the upregulation of CYP51A1 in DT cell lines. Differences in cholesterol
synthesis between parental and DT cells were then studied using a variety of
techniques including qPCR, western blotting, and cellular cholesterol assays. Total
cellular cholesterol and more specifically, mitochondrial cholesterol, were found to be
upregulated in DT cells, as well as parental cells treated with EGFR TKIs for as little as
48 hours. This upregulation of cholesterol synthesis was shown to be able to block the
release of cytochrome C and stop the initial induction of apoptosis by EGFR TKIs. We
then used the CYP51A1 inhibitor, ketoconazole, to downregulate cholesterol synthesis
in the cells. The cellular effects of a combination therapy of ketoconazole and EGFR
TKI was then studied in parental and DT cells. In both parental and DT cells,
ketoconazole and EGFR TKIs acted synergistically to induce apoptosis and overcome
the development of EGFR tolerance in these cells. Lastly, this combination therapy was
shown to shrink the growth of flank tumors in an in vivo mouse model of EGFR TKI
resistance. By studying the mechanisms of survival to initial EGFR TKI exposure, we
were able to better understand how lung cancer cells withstand EGFR TKI treatment
allowing time for the development of resistance and we used this knowledge to
strategize potential ways of sensitizing the cells to EGFR TKIs.
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CHAPTER 1:
INTRODUCTION

1.1 Objective
The objectives of this dissertation are 1) to create an in vitro model of epidermal
growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) treatment in lung cancer,
2) to examine the mechanisms of cell survival following EGFR TKI exposure, and 3) to
elucidate a method of overcoming acquired resistance to EGFR TKIs by eliminating the
ability of the cells to survive initial exposure.

1.2 Motivation
Drug resistance is common in NSCLC patients receiving treatment with EGFR TKI.
With the intent to investigate the development of drug resistance to these EGFR TKIs,
EGFR TKI tolerant human and mouse lung cancer cell lines have been developed as
models. The work presented herein will describe the molecular mechanisms that help
lung cancer cells initially survive exposure to EGFR TKIs and a method of targeting these
molecular mechanisms to block the development of EGFR TKI resistance.

1.3

Scope
The scope of this project is to gain a better understanding of the mechanisms

responsible for initial cell survival after exposure to EGFR TKIs and then use this
16

knowledge to identify treatments that are able to avoid or reverse development of drug
resistance to EGFR TKIs. Lung cancer is by far the deadliest cancer in the world and
novel treatment strategies can help in this battle. The work presented herein may one day
lead to a treatment capable of overcoming EGFR TKI resistance in the clinic by identifying
the molecular changes in lung cancer cells that upon exposure to EGF TKIs, are leading
to the development of resistance and means of stopping this development.

1.3 Overview
Chapter 2 will introduce background information on lung cancer and EGFR. Describing
the EGFR pathway, FDA approved EGFR TKIs, and known resistance mechanisms to
these EGFR TKIs. Chapter 3 will describe in detail, all experimental designs and methods
used. Chapter 4 will detail the development and characterization of EGFR TKI tolerant
lung cancer cell lines. Chapter 5 will explain the anti-apoptotic role of cholesterol in
helping the cells to survive the initial exposure to EGFR TKIs. Chapter 6 will introduce a
novel combination therapy to stop the development of EGFR TKI resistance. Chapter 7
will describe a meta-analysis of publicly available RNA sequencing datasets dealing with
EGFR TKI resistance in lung cancer, focusing on finding common pathways to the
development of EGFR TKI resistance across a number of different model systems.
Finally, chapter 8 will conclude this dissertation with a summary of all the results of this
study and highlight its contributions to EGFR TKI resistance research and the
development of new cancer therapies. The data contained within this dissertation comes
from 2 manuscripts, 1 which has been accepted for publication in FASEB BioAdvances
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and another which is going through peer-review at the International Journal of
Biochemistry and Cellular Biology [1, 2].
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CHAPTER 2:
BACKGROUND

2.1

Clinical Significance of Lung Cancer and Unmet Need for Treatment

According to the 2018 statistics from the American Cancer Society, more than 15.5
million Americans alive today have a history of cancer diagnosis [3]. In 2018, an
estimated 1.7 million people were newly diagnosed with cancer and about 600,000
people died from cancer in the U.S. [3]. In 2015 alone, the direct medical cost for cancer
in the U.S. was calculated to be over 80 billion dollars [3].
Lung cancer is the second

Table 1
Top 3 Cancer Sites of Estimated New Cases (% of
Total)
Cancer Type

Male

Females

Prostate (Male)/
Breast (Female

164,690 (19%)

266,120 (30%)

Lung and
Bronchus

121,680 (14%)

112,350 (13%)

Colon and Rectum

75,610 (9%)

64,640 (7%)

most

common

type

of

cancer in men and women,
with
cases

over

200,000

expected

diagnosed

in

new

to

be

2018

[3]

(Table 1). However, it is by

far the deadliest type of cancer in both men and women, according to the most recent
statistics, it was estimated to cause over 154,000 deaths in 2018 [3] (Table 2). With almost
19,000 new cases and 12,000 of these deaths coming from the population of Florida
alone [3]. This represents the second highest of any state, trailing only California. On
average, about 70 out of every 100,000 people in Florida will be diagnosed with lung
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cancer and 50 of these people will go on to die from the disease [3]. The five-year survival
rate for patients with lung cancer is one of the lowest of any cancer at 18.6%, while the
Table 2

overall five-year survival for cancer

Top 4 Cancer Sites of Estimated New Deaths
(% of Total)

patients is 66.9% [3]. While progress

Cancer Type

Male

Females

Lung and
Bronchus

83,550 (26%)

70,500 (25%)

Prostate
(Male)/
Breast
(Female

29,430 (9%)

40,920 (14%)

Colon and
Rectum

27,390 (8%)

23,240 (8%)

Pancreas

23,020 (7%)

21,310 (7%)

has been made, increasing the 5year survival rate from 12% in 1975
to almost 20% today, much of this
can be credited to the decline in
smoking

overall

[3]

(Table

3).

Smoking is the largest risk factor for
both small cell and non-small cell
lung cancer, age should also be

considered as the majority of diagnoses are made in patients over 65 and very rarely in
patients younger than 45 [3].
Non-small

Table 3

cell
5-Year Survival Rate (%) By Stage of Diagnosis

lung
cancer

Cancer Type

ALL
STAGES

LOCAL

REGIONAL

DISTANT

Lung and
Bronchus

18%

56%

29%

4%

(NSCLC)
accounts for

about 80–85% of all lung cancer cases [4]. NSCLC patients are usually initially treated
with platinum based chemotherapeutic regimen that all too often fail to cure the disease
[5, 6]. Over half of lung cancer patients die within one year of diagnosis [3]. The major
reason for this outcome is the development of drug resistance [5]. When cancer cells
20

develop resistance to a specific treatment, the patient’s tumor will begin to grow again
despite ongoing treatment. Cancer treatment has historically relied on the use of these
nonspecific, toxic drugs to treat patient’s tumors, however recent trends in oncology have
favored the development of less toxic, molecularly targeted agents [7, 8]. Despite this
advancement, the use of these drugs has only been associated with only a 1.5-year
average increase in survival [9]. This is because no treatment developed thus far is
immune to the development of resistance.
The failure of lung cancer treatments can be attributed partly to the development
of drug resistance; however, the underlying cellular and molecular mechanisms are also
poorly understood. Due to cancer’s genetic instability and composition of a very diverse
population of cells, new mutations are able to arise in response to treatments, allowing
cells containing them to continue to grow and expand [5]. There is a great unmet need to
develop novel treatments specifically to overcome drug resistance and prevent patient
relapse. Through their ability to target multiple pathways or multiple elements of the same
pathway simultaneously, combination therapies may prevent any single new mutation that
arises from conferring drug resistance [5, 10]. This leads to the present challenge of
finding drug combinations that are effective without being overly toxic to healthy cells.
While work remains ongoing, the development of improved models to study drug
resistance will be vital in the search for effective combination therapies.

2.2

Epidermal Growth Factor Receptor (EGFR) and Lung Cancer

EGFR is a 170kDa glycoprotein found in the erbB receptor tyrosine kinase family [11].
The family includes four members: ErbB1 (EGFR), ErbB2/HER2/Neu, ErbB3/HER3, and
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ErbB4/HER4 [11]. EGFR is a cell-surface receptor that is divided into three regions: an
extracellular ligand binding region, a transmembrane region, and an intracellular region
containing a tyrosine kinase domain [11]. The extracellular region of EGFR is composed
of 4 domains that function in recognition and binding of ligands belonging to the EGF
family of growth factors [11]. These include, epidermal growth factor (EGF), transforming
growth factor α (TGF-α), amphiregulin (AR), heparin-binding EGF (HB-EGF), epiregulin
(EPR), and betacellulin (BTC) [11]. Binding of any of these ligands causes activation of
the receptor into an active signaling complex [11].
Receptor activation occurs through domains 1 and 3, with domain 1 responsible
for initial ligand binding and domain 3 responsible for additional ligand binding to
strengthen the interaction [11]. Ligand binding causes exposure of the dimerization
interface on domain 2 for coupling with domain 2 of the other active receptor, which can
be EGFR or any of the other erbB family members [11]. Dimerization brings the
intracellular tyrosine kinase domain into complex with the intracellular tyrosine kinase
domain on the dimerization partner, which then activates one of the tyrosine kinase
domains that starts a chain reaction, that then activates the second tyrosine kinase
domain and so on [11]. Ten phospho-tyrosine amino acids serve as docking sites for
adaptor

proteins,

which

activate

two

major

transduction

pathways:

the

Ras/Raf/MEK/MAPK and the PI3K/Akt/mTOR pathways [11]. These pathways activate
genes that are responsible for cell proliferation, survival, and differentiation [12].
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Figure 1: erbB Receptor Tyrosine Kinase Family Signaling
Members of the erbB family of receptors and their associated ligands. When
activated by ligand binding, they promote cell survival and proliferation
through the PI3K/AKT and RAS/MEK pathways.

Figure 1 shows all members of the erbB receptor tyrosine kinase family and the
ligands that each receptor is known to bind, as well as the downstream signaling events
caused by receptor activation. Ligands have been identified that bind to EGFR, HER3,
and HER4, however no ligand has been identified for HER2 [13]. It has been found that
cells expressing HER2, HER3, or HER4 homodimers do not induce tumor growth, cells
expressing EGFR homodimers induce limited tumor growth, and HER2/HER3
heterodimers can inducing tumor growth, while HER1/HER3 and HER1/HER4 cannot
induce tumor growth [13]. However, EGFR/ HER2 heterodimers produce the most
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aggressive tumor growth and due to its increased ability to form heterodimers with the
other HER family members, heterodimerization with HER2 is preferred by all of the HER
family receptors [13].
In the normal physiological environment EGFR plays a critical role in epithelial cell
physiology [12]. It is mutated and/or overexpressed in different types of human cancers,
including glioblastoma, brain, lung, breast, and ovarian [14]. EGFR mutations and genetic
rearrangements can cause sustained activation of downstream signaling via altered
receptor endocytosis and trafficking, disrupted receptor ubiquitination and lysosomal
degradation, or ligand-independent receptor activation [14]. Tumors from patients with
NSCLC can be screened for the presence of EGFR mutations, which commonly occur in
exon 19 as an in frame deletion or exon 21 as a point mutation (L858R) [15]. About 20%
of all NSCLC patients are expected to harbor an EGFR activating mutation [15]. Clinically
relevant EGFR activating mutations include, deletions in exon 19 that cause elimination
of the amino acid motif, LREA, and point mutations in exon 21 that substitute arginine for
leucine at position 858 (L858R) [16]. These two mutations account for about 85% of
EGFR mutations in the NSCLC and make EGFR constitutively active and oncogenic [16].

2.3

EGFR Tyrosine Kinase Inhibitors (TKIs)

EGFR inhibitors have been shown to provide clinical benefits over chemotherapy for lung
cancer patients with EGFR activating mutations [17]. The number of lung cancer patients
who harbor an EGFR mutation and are expected to respond to EGFR targeted therapy is
around 14–20% [18, 19]. Monoclonal antibodies targeting EGFR were the first anti-EGFR
therapies to be used in the clinic [11, 20]. Anti-EGFR antibodies bind to the ligand binding
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regions of EGFR with high affinity and compete with the normal ligands to block EGFR
activation, induce receptor internalization and downregulation, and can recruit effector
cells of the immune system that induce a cytotoxic immune response [11, 20] (Figure 2).
Examples of clinically approved anti-EGFR antibodies include, Cetuximab, a chimeric
mouse/human IgG1 antibody, Panitumumab, a humanized IgG2 mAb and, Nimotuzumab,
a humanized IgG1 antibody [11, 20].

Figure 2: Mechanism of Action for EGFR TKIs
EGFR TKIs block downstream signaling in the pathway by binding to the
intracellular tyrosine kinase domain of EGFR and stopping its activation.

Small molecule anti-EGFR agents, EGFR TKIs, are irreversibly or reversibly
directed against the catalytic domain of EGFR [11, 20]. First generation- (gefitinib[21],
erlotinib[22], lapatinib[23]), second generation- (afatinib[24]), and most recently thirdgeneration (osimertinib[25]) EGFR TKIs are clinically approved to treat NSCLC patients
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[26]. Figure 2 illustrates the mechanism of action for EGFR TKIs, which work by binding
to and blocking the ATP-binding site preventing tyrosine kinase activity and downstream
signaling [11, 20]. Lapatinib is a special case, as it is qualified as a dual TKI, which
interrupts the HER2 and EGFR pathways, and is commonly used to treat patients with
metastatic breast cancer whose tumors overexpress HER2 [27]. Lapatinib has also been
shown to increase the efficacy of the EGFR blocking monoclonal antibody trastuzumab,
as well as other chemotherapeutic drugs in breast cancer patients [28-30]. Lapatinib is
not yet approved to treat EGFR overexpressing lung cancer, as the other EGFR TKIs
mentioned above are [11, 20].
Human cells have two major apoptosis signaling pathways: the extrinsic or death
receptor pathway and the intrinsic or mitochondrial pathway [31, 32]. The intrinsic
pathway exerts its apoptotic effects via mitochondrial outer membrane permeabilization
(MOMP) and the release of cytochrome c, activation of the caspase cascade and cellular
death [31, 32]. For MOMP to occur, a number of Bcl-2 family proteins must be engaged
[31, 32]. Members of the Bcl-2 protein family are distinguished by the presence or
absence of different Bcl-2 domains [31, 32]. Proapoptotic Bcl-2 proteins, Bax and Bak,
can induce MOMP, however, to prevent unwanted cell death, in the absence of
proapoptotic signals Bax and Bak are bound and inhibited by anti-apoptotic Bcl-2 proteins
(Bcl-2, Bcl-xL, and Mcl-1) [31, 32]. Lastly, the BH3-only proteins of the Bcl-2 family, are
usually divided into direct activators (Bid and BIM) and de-repressors (Bad, NOXA, and
PUMA) [31, 32]. Activators can directly induce Bak and Bax activation, whereas derepressors initiate apoptosis by binding and neutralizing anti-apoptotic Bcl-2 family
members, so they can no longer inhibit Bak and Bax, thus allowing activation of Bax and
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Bak [31, 32]. Regulation mechanisms that serve to control levels and activation of these
Bcl-2 family proteins include, up-regulation, degradation, and phosphorylation [31, 32].

Figure 3: EGFR TKIs and Apoptosis
EGFR TKIs promote apoptosis by decreasing the production of anti-apoptotic
BCL-2 thus allowing the BAK/BAX complex to become activated and initiate
mitochondrial permeabilization.

EGFR TKIs have been shown to mediate their apoptotic effects via the intrinsic
pathway through inhibition of Akt and ERK dependent pathways that cause changes in
the expression level of Bcl-2 family members and allow for activation of apoptosis [31,
32]. Figure 3 shows one of the mechanisms by which EGFR TKIs are known to induce
cellular apoptosis in EGFR mutant cancer cells. After the EGFR TKI is bound it stops
EGFR downstream signaling through the receptor, thus inhibiting AKT signaling, which
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downregulates anti-apoptotic BCL-2 family proteins that are responsible for binding and
inhibiting BAX and BAK. Once activated, BAX and BAK are then free to cause MOMP
and activate apoptotic cell death.

2.4

Drug Resistance to EGR TKIs

Despite the initial clinical responses to these EGFR targeted therapies, long-term efficacy
is not possible because acquired drug resistance hampers the effectiveness of these
therapies [15, 26]. Drug resistance has, in nearly all cases, stifled treatment for EGFR
mutated NSCLC [15, 26]. In most cases, patients treated using first or second generation
TKIs become completely resistant in around 9-13 months [15, 26]. Recently, thirdgeneration EGFR inhibitors, such as osimertinib, have emerged as potential therapeutics
to block the growth of EGFR mutants that do not respond to previous generation EGFR
TKIs [15, 26]. However, these have also proven to be susceptible to the development of
drug resistance [15, 26]. Each succeeding generation was developed to combat
resistance issues of the previous generations.
Target alteration, increased ligand production, increased downstream pathway
activation, and alternative pathway activation have all been proposed as mechanisms of
resistance to EGFR TKIs [15, 26] (Figure 4). The common EGFR mutations that confer
primary resistance to EGFR TKIs include, exon 19 mutations L747S/D761Y, exon 20
T790M, and the exon 21 mutation T854A [33]. Non-EGFR mutation dependent
mechanisms of primary resistance include, deletion of tumor suppressor gene PTEN,
PIK3CA mutations, activation of the NFκB pathway, polymorphisms of pro-apoptotic
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Figure 4: EGFR TKI Resistance Mechanisms
EGFR TKI resistance develops when EGFR or downstream signaling proteins
acquire activating mutations or when parallel alternative pathways become
activated.

protein BIM, increased expression of HGF, increased MET-mediated activation, KRAS
mutations, BRAF mutations, ALK translocation, and overexpression of HGF [33]. About
50% of NSCLC patients treated with EGFR TKIs will develop resistance due to the T790M
mutation, which causes resistance to EGFR-TKIs is by increasing the affinity to ATP over
the EGFR TKIs, which are competing with ATP for binding [33]. EGFR TKIs are the
standard of care for patients harboring EGFR-sensitizing mutations, but as it stands
today, in the majority of cases, resistance is almost inevitable.
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2.5

Concluding Remarks

Despite a gradually increasing knowledge of how EGFR TKI resistance forms in patients,
there has been very little success in overcoming it and it is probable that many routes are
yet to be discovered. Development of novel therapies to overcome EGFR TKI resistance
holds great promise to improve clinical outcomes. To efficiently study the development of
EGFR TKI resistance accurate models are needed. We hypothesize that a better
understanding of the mechanisms responsible for initial cell survival after exposure to
EGFR TKIs may help identify treatments that are able to avoid or reverse development

Figure 5: Development Course of EGFR TKI Resistance
To develop EGFR TKI resistance, naïve cells must first survive the initial exposure to
EGFR TKIs by upregulation of pro-survival and anti-apoptotic pathways, which allows
the cell time to acquire mutations that confer resistance or activate redundant
pathways to EGFR.

of drug resistance in the clinic. The goal of this study is to look beyond the well-studied
mechanisms of resistance to EGFR TKIs and focus on alternative mechanisms of early
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stage tolerance that allow the cells to survive and tolerate the interim treatment period
until true resistance can be established (Figure 5). This strategy may be exploited to
design more efficient treatment regimens. Upon completion of this project, we will achieve
a better understanding of EGFR TKI resistance and possible ways to overcome the
development of this resistance.
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CHAPTER 3:
GENERAL METHODS

This section presents the general molecular biology techniques used during the study.
3.1

In vitro Studies:

3.1.1 Amplex Red Cholesterol Assay
Cell pellets were collected, and cholesterol content was extracted using a 30:20 solution
of Hexane/Isopropanol. Cholesterol content was determined using the Amplex Red
Cholesterol Assay Kit (Thermo Fisher Scientific) according to the manufactures' protocol.
3.1.2 Cell culture- Monolayer and FiSS
Cell lines were obtained from the American type culture collection (ATCC). Cells were
cultured in a humidified incubator at 37⁰C in a 5% CO2 atmosphere (Thermo Fisher
Scientific). Cells were cultured in tissue culture treated well plates and dishes (Thermo
Fisher Scientific) in the appropriate complete cell culture media (DMEM or RPMI
containing 10%FBS and 1% penicillin/streptomycin) (Hyclone). Cells were split at about
90% confluency and media was changed every 3-4 days. The Fiber Inspired Smart
Scaffold (FiSS) was prepared as previously described [34, 35]. For cell culture
preparation, scaffolds were placed in non-tissue culture treated well plates (USA
Scientific), sterilized in ethanol, washed twice with PBS, additionally sterilized under UV
light for at least 45 minutes, and then incubated in cell culture media overnight in a
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humidified incubator at 37⁰C in a 5% CO2 atmosphere (Thermo Fisher Scientific). Cells
were seeded onto the FiSS the next day in the appropriate complete cell culture media.
3.1.3 Cell Titer Glo IC50 Assay
Cells were treated in duplicates with varying concentrations of the identified drug for 48
hours in monolayer cultures and for 48 hours in FiSS cultures. For cells grown on the
FiSS, drugs were added on day 5, as compared to 24 hours for monolayer. Cell viability
was determined using Cell Titer Glo assay (Promega) according to the manufactures’
protocol. Luminescence was measured in a white well-plate in a Bio-Tek Synergy H4
plate reader. Drugs were obtained from LC Laboratories and Sigma Aldrich.
3.1.4 Drug Tolerant (DT) Cell line Generation
Cells were grown in the appropriate complete cell culture media containing the highest
static concentration of the respective EGFR TKI that they would still proliferate in for 20
days and used for experiments from day 21 to day 60.
3.1.5 Flow cytometry
All flow cytometry experiments were performed using a Becton Dickenson (BD) FACS
Canto II system at the University of South Florida COM Fred Wright Jr Flow Cytometry
Core. All analysis for flow cytometry experiments was done using FlowJo 8.7 software
(FlowJo).
3.1.5.1 Annexin V Assay
Parental- and DT- cell lines were treated with the indicated concentrations of lapatinib for
24 hours in monolayer cultures. They were then stained for Annexin V and PI using the
FITC Annexin V Apoptosis Detection Kit I (BD Pharmingen) or the eBioscience™ Annexin
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V Apoptosis Detection Kit APC (Thermo Fisher Scientific) according to the manufactures'
protocol.
3.1.5.2 JC-1 Assay
Cells were treated with lapatinib and/or ketoconazole for 48 hours in monolayer cultures.
They were then stained with JC-1 (Thermo Fisher Scientific) according to the
manufactures' protocol.
3.1.6 Ingenuity Pathway Analysis
Ingenuity Pathway Analysis (IPA) (Qiagen) was used for analysis and interpretation of the
acquired differential expressed genes lists from RNA sequencing [36]. A detailed
description of this software is available at ingenuity.com. A core analysis was performed
on each dataset and a comparison analysis was then performed comparing all ten
datasets. Affected canonical pathways and likely upstream regulators responsible for
observed gene expression changes were explored. They were sorted according to their
average Z scores, which are statistical measures of the match between expected
relationship direction and observed gene expression. Heatmapper software was used to
produce heat maps from the data obtained from IPA [37]. A detailed description of this
software is available at heatmapper.ca. We then used the My Pathway/Path Designer
tools in IPA to plot all known interactions between the pathway and EGFR. The sum of
each genes fold change compared to control from each dataset was used to color the
genes. To explore these pathways further we produced a list containing significantly
changed genes that are commonly up or down regulated in 6 or more of the RNASeq
datasets and added the significantly changed proteins from the PhosphoExplorer array.
We then used the My Pathway/Path Designer tools in IPA to plot all known interactions
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between the list and EGFR. The data from the comparison analysis was used to color the
genes based on up or down regulation. Data from the PhosphoExplorer array was used
to color the proteins based on up or down regulation. Known pathways in IPA for cellular
signaling/ metabolic processes were then overlaid on this plot and we kept only genes or
proteins that directly interacted with our pathways of interest. Finally, we produced a gene
map showing genes that were commonly up or down regulated in six or more datasets
but have no experimentally validated known interactions with the EGFR pathway in the
IPA database. A literature search was then performed on the upregulated genes to
determine any roles these genes may play in resistance to EGFR TKIs.
3.1.7 Mass Spectroscopy
Whole cell lysate for each cell line was run in duplicate. Peptides for each sample were
labeled using ITRAQ labeling kit. Data was collected using the Q Exactive Plus mass
spectrometer and analyzed first using MaxQuant proteomics software and next uploaded
into Scaffold software for statistical analysis. Identified proteins were first subjected to a
mann-whitney u-test to look for significant differences in protein abundance. Protein
abundance is measured by the average intensities between replicates. Proteins that were
identified to have a p-value of p≤.05 were further analyzed to characterize the fold change
difference between the groups.
3.1.8 Mitochondrial Isolation
Cell pellets were collected, and mitochondria were extracted using the Mitochondria
Isolation Kit for Cultured Cells (Thermo Fisher Scientific) according to the manufactures'
protocol.
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3.1.9 Nuc Blue Fluorescent Microscopy
Tumoroid formation was assessed using fluorescent microscopy (EVOS Thermo Fisher
Scientific) after nuclear staining with Nuc Blue dye (Thermo Fisher Scientific).
3.1.10 Phospho-Explorer Antibody Array
Tumors from each treatment group were snap frozen on dry ice and stored at 150°C.Total protein was extracted from tumors using RIPA buffer (Thermo Fisher
Scientific) according to the manufactures’ protocol. Protein concentration was determined
using the Pierce Coomassie Protein Assay Kit (Thermo Fisher Scientific) according to the
manufactures’ protocol. Tumor protein samples from each group were then equally
pooled (N=3) and protein expression was determined using the Phospho-Explorer
Antibody Array (Full Moon Biosystems, California USA) according to the manufactures’
protocol). Cy-3 developed array chips were scanned, and images were analyzed using
ImageJ to determine relative normalized staining intensity for each antibody. β-actin was
used as a house keeping gene to quantify relative protein expression. Average relative
fluorescent units ±SEM (N=2) were calculated for each protein. Statistical significance for
each experiment was determined using two-way analysis of variance (ANOVA) and the
Bonferroni post hoc test * = p<0.05, ** = p<0.01, *** = P<0.001. Calculations were
performed and graphs produced using Prism 6.0 software (GraphPad, California USA).
Graphs of results show the mean and error bars depict the average plus or minus the
standard error of the mean.
3.1.11 Quantitative Reverse Transcriptase PCR (qPCR)
Total cellular RNA was extracted from cell pellets using Trizol (Thermo Fisher Scientific).
RNA was then quantified using the Nanodrop (Thermo Fisher Scientific). One microgram
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of RNA was then reverse transcribed using the Maxima cDNA Reverse Transcription Kit
(Thermo Fisher Scientific). qPCR performed on the cDNA was used to quantitate the
relative

expression

levels

of

certain

genes

to

hypoxanthine-

guanine

phosphoribosyltransferase (HPRT) or -actin as a control. Real time analysis was
performed using BlazeTaq™ SYBR® Green qPCR Mix 2.0 (Genecoepia) in a Bio Rad
CFX-384 thermocycler using primers obtained from Integrated DNA Technologies (IDT).
(See Table 4 for primer sequences). The data was analyzed using ΔCt and ΔΔCt
calculations and expression of all genes was normalized to HPRT expression as a
housekeeping gene. Data analysis was performed using the CFX Maestro software (BioRad).
3.1.12 RNASEQ Dataset Acquisition and Analysis:
RNA-Sequencing datasets were downloaded from the National Center for Biotechnology
Information (NCBI) Gene Expression Omnibus (GEO) database (ncbi.nlm.nih.gov/geo/)
[38]. The .fasta files were downloaded and then analyzed for differential gene expression
using tools available on the public server at usegalaxy.org, an open-source web-based
platform [39]. The raw sequencing data was processed to remove any adaptor, PCR
primers and low-quality transcripts using FASTQC[40] and Trimmomatic[41]. The
samples were then aligned against human genome using HISAT2[42]. Gene expression
measurement was then performed from aligned reads using featureCounts[43].
Differential gene expression was calculated using DESeq2[44]. Genes were considered
significantly differentially expressed if the corrected p-value was <.05.
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3.1.13 Western immunoassay
3.1.13.1 WES Automated Capillary Western Blotting
Total protein was extracted from cells using RIPA buffer (Thermo Fisher Scientific)
according to the manufactures’ protocol. Protein concentration was determined using the
Pierce™ Coomassie Protein Assay Kit (Thermo Fisher Scientific) according to the
manufactures’ protocol. The expression of the indicated proteins was determined using
the WES (Protein Simple) automated western blotting system according to the
manufactures’ protocol. Total protein expression was analyzed using area under the
curve (AUC) measurements generated using Compass software for Simple Western
(Protein Simple). Housekeeping genes were used to quantify relative protein expression.
3.1.13.2 Traditional Western Blotting
Total protein was extracted from cells using RIPA buffer (Thermo Fisher Scientific)
according to the manufactures’ protocol. Protein concentration was determined using the
Pierce™ Coomassie Protein Assay Kit (Thermo Fisher Scientific) according to the
manufactures’ protocol. Proteins (30g) were resolved by SDS-polyacrylamide gel
electrophoresis (Bio-Rad) and transferred to a nitrocellulose membrane (Bio-Rad). Blots
were blocked in PBST (PBS plus 0.05% Tween 20 (Sigma Aldrich)) containing 5% instant
milk and incubated with primary antibody in PBST overnight at 4 Celsius. Proteins
recognized by the antibody were detected by SuperSignal™ West Pico PLUS
Chemiluminescent Substrate (Thermo Fisher Scientific) using a horseradish peroxidasecoupled secondary antibody (Santa Cruz Biotechnology) according to the manufactures’
protocol. Housekeeping genes were used to quantify relative protein expression.
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3.2

In Vivo Studies:

3.2.1 Animal Experiments
C57BL/6 mice were purchased from Envigo. Mice were injected subcutaneously on the
flank with 1 million LLC cells. Nu/Nu nude mice were purchased from Envigo. Mice were
injected subcutaneously on the flank with 3 million H1650 cells. Mice began treatment
when tumors became palpable (2-3mm diameter). Mice were treated every day with
vehicle control, 50mg/kg lapatinib, 20mg/kg ketoconazole, or a combination of both until
collection. Drugs were injected peritoneal. Drugs were dissolved in 0.1% Tween 20 with
5%DMSO in water. Tumors were collected when controls reached 10mm X 10mm. To
obtain single cell suspensions of tumors they were then digested using the MACS Miltenyi
Biotec Mouse Tumor Dissociation kit and gentle MACS Dissociator according to the
manufactures’ protocol. Cells were then plated on the FiSS and drug sensitivity
experiments were performed as described previously. Animals were housed in the
University of South Florida comparative medicine facility at the Morsani College of
Medicine and all protocols were reviewed and approved by the USF institutional animal
care and use committee.
3.3

General Statistics:

3.3.1 Statistics
Experiments have been repeated at least twice. When comparing just two groups, such
as DT vs parental or treated vs control, statistical significance for each experiment was
determined using a paired t-test for paired data, unpaired t-test for unpaired data, or a
Mann-Whitney test when the data was not normally distributed, * = p<0.05, ** = p<0.01,
*** = P<0.001, **** = P<0.0001. When comparing multiple groups statistical significance
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for each experiment was determined using Analysis of variance (ANOVA) and the Tukey
post hoc test when comparing the mean of each group with the mean of every other
group, the Bonferroni post hoc test when comparing means of preselected groups, or a
Kruskal-Wallis test and the Dunn’s post hoc test when the data was not normally
distributed * = p<0.05, ** = p<0.01, *** = P<0.001, **** = P<0.0001. Calculations were
performed and graphs produced using Prism 6.0 software (GraphPad, California USA).
Graphs of results show the mean and error bars depict the mean plus or minus the
standard error of the mean.
Table 4: Human Primer Sequences Used for Quantitative Real Time
PCR
Gene
Strand
Primer Sequence
β-Actin
DHCR7
DHCR24
HPRT
LSS
SREBF2

Forward

CAAACATGATCTGGGTCATCTTCT

Reverse

CAAACATGATCTGGGTCATCTTCT

Forward

ACATGCTCGGCTCTCGGAC

Reverse

AGGTATAGAGCTGGGCGGCT

Forward

ATCGCAGCTTTGTGCGATG

Reverse

CACCAGGAAACCCAGCGT

Forward

GAAAGGGTGTTTATTCCTCATGG

Reverse

CAGTGCTTTGATGTAATCCAGCAG

Forward

GGCAGACGTGGACCTACC

Reverse

GAAAAGTGGGCCACCATAATC

Forward

CCCTTCAGTGCAACGGTCATTCAC

Reverse

TGCCATTGGCCGTTTGTGTC

Table 5: Antibodies Used in Immunoblotting
Protein

Company

Catalog Number

AKT

Cell Signaling

4685

p-AKT

Cell SIgnaling

4060

α-actinin

Santa Cruz Biotechnology

Sc-17829

βc-1782

Sigma-Aldrich

A2228

Cleaved Caspase-9

Cell Signaling

9501P

Cox IV

Novus Biologicals

NBP2-43540
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Table 5 (Continued): Antibodies Used in Immunoblotting
Cytochrome c

Novus Biologicals

MAB897

CYP51A1

Sigma-Aldrich

HPA041325

DHCR24

Abcam

Ab40490

EGFR

Cell Signaling

4267

p-EGFR

Cell Signaling

3777

LSS

Abcam

Ab80364

ERK1/2

Cell Signaling

4695

p-ERK1/2

Cell Signaling

4370

PARP1

Cell Signaling

9542

SREBP2

Abcam

Ab30682

Survivin

Cell Signaling

2808

Vinculin

Santa Cruz Biotechnology

Sc-25336

Anti-Mouse

EMD Millipore

2854655

Anti-Rabbit

Santa Cruz Biotechnology

Sc-2357
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CHAPTER 4:
EGFR TKI DRUG TOLERANCE (DT) MODEL

4.1 Introduction
Lung cancer is the 2nd most common cancer in both men and women, however it
is the number one cause of cancer related death in both males and females [3]. Most
cancer patients are initially treated with chemotherapeutic drugs that all too often fail to
cure the disease, with the major reason for this outcome being the development of drug
resistance [5]. Tyrosine kinase receptor homodimer and heterodimer activation induces
differentiation and cell proliferation and is thought to be a major factor in the development
of certain cancerous cells [11]. It is known to have an important role in breast cancer,
colorectal cancer, non-small cell lung cancer, squamous cell carcinoma of the head and
neck, and pancreatic cancer [14]. To treat these cancers multiple EGFR TKIs have been
FDA approved, including, lapatinib, gefitinib, erlotinib and most recently, osimertinib. The
long-term effectiveness of these therapies is plagued by acquired drug resistance [15,
45].
Therapeutic resistance to EGFR TKIs often occurs within the first several months
of therapy and to date, many methods of drug resistance have been proposed [46]. For
example, target alteration, increased ligand production, and increased downstream
pathway activation have all been proposed as mechanism of resistance [46]. Many
different cell line models have been developed to study EGFR TKI resistance in lung
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cancer [47-52]. These EGFR TKI resistant cell lines were obtained via different protocols
and each protocol was developed and verified by the respective authors. In one study,
KE Ware et, al. established gefitinib resistant lung cancer cell lines through a chronic
adaptation model in which the cells were exposed to step-wise increasing concentrations
of gefitinib until they could routinely be cultured in a concentration of 3M [52]. This led
the authors to discover that these cells undergo an induction of FGFR1-FGF2 autocrine
signaling pathway, which is sufficient to confer resistance to gefitinib and drive cancerous
growth in presence of the drug. In another study, Kyung-A Song et. al. created gefitinib
tolerant lung cancer cell lines by exposing the cells to 50nM gefitinib for 6 days and then
withdrawing the drug for the next 3 days [51]. Using this model, the authors show that the
gefitinib tolerant cells upregulate expression the anti-apoptotic protein, MCL-1. This
allows the cells to survive the short-term apoptotic pressure of gefitinib and allows them
time to acquire a secondary resistance mechanism that will allow them to grow in
presence of the gefitinib. Matias Casas-Selves et. al. used a loss-of-function, whole
genome shRNA screen, to identify the canonical Wnt pathway, particularly the poly-ADPribosylating enzymes tankyrase 1 and 2 that positively regulate canonical Wnt signaling,
as crucial to cell survival during initial exposure to gefitinib [53]. This model exposed the
cells to gefitinib for 2 days at concentrations that would normally inhibit expansion by
~70%, followed by 4 days without gefitinib. In one last example, Aaron N Hata et. al.
created gefitinib tolerant, intermediate resistant, and late resistant cell pools, which
allowed them to study the distinct evolutionary paths that can lead the cells to becoming
resistant to gefitinib [48]. The authors found that EGFRT790M-positive clones could arise
from the selection of pre-existing clones or from initially EGFRT790M-negative drug-tolerant
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cells. The authors hypothesized that the initial mechanisms that promote survival of the
drug-tolerant cells may be sufficient to prevent apoptosis but may not fully recapitulate
the oncogenic signaling provided by EGFR, so these cells provide a reservoir of cells from
which genetic mechanisms of acquired resistance can evolve. This is most likely due to
the fact that all of these EGFR TKI resistant models were produced using different
methods and EGFR TKIs, along with different lung cancer cell lines. These studies serve
as examples to highlight the variability in EGFR TKI resistant model generation and the
wide array of genetic changes that can lead to EGFR TKI resistance. However, despite
this gradually increasing knowledge, many routes are yet to be discovered, hence
additional drug resistance mechanisms still need to be uncovered to elucidate a method
of overcoming this recurring issue [7]. Understanding drug resistance mechanisms will
help design more efficient combination treatment strategies that will help block resistance
[10, 26].
We hypothesize that a better understanding of the mechanisms responsible for
initial cell survival after exposure to EGFR TKIs may help identify treatments that are able
to avoid or reverse development of drug resistance in the clinic. The goal of this study is
to look beyond the well-studied mechanisms of resistance to EGFR TKIs, such as
mutations in the EGFR receptor (T790M, C797S), activation of EGFR downstream
proteins (MEK, AKT, PI3K), activation of alternative tyrosine kinase pathways (HER2,
MET, AXL), and activation of growth factor receptors (FGFR, IGF1R) [54]. We will focus
on alternative mechanism of survival to EGF TKIs that allow the cells to survive intial
exposure, giving them time to develop traditional mechanisms of resistance. Our goal is
the discovery potential novel mechanisms leading to resistance to EGFR TKIs and to use

44

this knowledge to develop a novel therapy that will overcome the development of
resistance. Lung cancer cell lines containing different EGFR mutations (H1650 and
H1975) in addition to EGFR wild type cell lines (H1299 and LLC1), will be used to
represent a range of NSCLCs (Table 6). These cell lines also harbor other cancerous
driver mutations including, cyclin dependent kinase inhibitor 2A (CDKN2A) (H1650 and
H1975), KRAS Proto-Oncogene (KRAS) (LLC), NRAS Proto-Oncogene (NRAS) (H1299
and LLC), phosphatidylinositol 3-kinase catalytic alpha polypeptide (PIKC3A) (H2975 and
LLC), and tumor suppressor p53 (TP53) (H1650 and H1975). Also, of note, H1299 cells
have stable expression of luciferase and green fluorescent protein (GFP) and LLC cells
have stable expression of luciferase. These two cell lines were purchased from
Genecopoeia (H1299) and PerkinElmer (LLC).

Table 6: Lung Cancer Cell Lines Used in This Study
Driver Mutations
CELL
LINES

SPECIES

H1650

Human

H1975

Human

c.205G>T

c.2369C>T
c.2573T>G

Wild-Type

Wild-Type c.353G>A c.205G>T

H1299

Human

Wild-Type

Overexpress

Wild-Type

c.181C>A Wild-Type

LLC

Mouse

Wild-Type

Overexpress

p.G12Chet p.Q61Hhet Wild-Type Wild-Type

CDKN2A

EGFR

KRAS

c.1_471del471 c.2235_2249del15 Wild-Type

NRAS

PIK3CA

Wild-Type Wild-Type

TP53
c.6732A>G

Deletion

Previously our lab has developed a Fiber Inspired Smart Scaffold (FiSS) culture
environment, that creates a more representative model of tumor growth and drug
resistance [35, 55]. We found that this FiSS platform allows for the growth of three45

dimensional (3D) tumor-like aggregates (tumoroids), which resemble in vivo tumors.
The FiSS platform even allows for growth of tumor biopsy cultures, which contain not
only the cancer cells, but also the tumor stromal cells that are known to modulate the
acquisition of drug resistance[56]. Using the FiSS along with our cell line models of
acquired EGFR TKI resistance, novel treatments targeting drug resistance can be
identified. The development of these novel therapies to overcome drug resistance holds
great promise to improve patient outcomes.

4.2

Results

To investigate drug resistance to EGFR TKIs, we have developed lapatinib and gefitinib
tolerant human lung cancer cell lines as models for de novo drug resistance. To derive

Figure 6: Establishment of EGFR TKI Tolerant Cell Lines
EGFR TKI tolerant cell lines were established by culturing the cells in fixed
concentrations of TKI for a period of 20-60 days.
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EGFR TKI drug tolerant (DT) cells, three human lung cancer cell lines (H1650, H1299,
and H1975) and one mouse lung cancer cell line (LLC) with different and/or no EGFR
activating mutations were grown in static concentrations of the respective EGFR TKI for
a minimum of 20 days and up to 60 days (Figure 5).
We first performed IC50 analysis of parental vs DT cells in each cell line (H1650,
H1299, H1975, and LLC) to get an idea of the level of resistance that 20-60-day exposure

Figure 7: Lapatinib Sensitivity of Lapatinib Tolerant Cell Lines
A-E) Lapatinib sensitivity in parental and lapatinib DT cell lines. (A) H1650
(N=6), (B) H1299 (N=8), (C) H1975 (N=6), and (D) LLC (N=3) cells were
treated the day after seeding with varying concentrations of the lapatinib for
48 hours. Average IC50 value ±SEM is shown. Average IC50 value is shown
(E). Statistical significance for each experiment was determined using an unpaired T-Test comparing each parental cell line to the corresponding DT cell
line, * = p<0.05, ** = p<0.005, *** = P<0.0005.
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to lapatinib or gefitinib would confer. Cells were plated and varying concentrations of the
respective EGFR TKI (1.25-80uM) was added the following day. Cell Titer Glo (Promega)
was used to determine the relative cell number in each well after 48 hours of drug
exposure. To calculate IC50 for each cell line we used GraphPad Prism. Average
luminescence value for each group was plotted as a percentage of the control or
untreated group. A non-linear regression was then run to calculate the IC50 value. A
comparison of the drug sensitivity showed that H1650 and H1299 DT cells were about 2fold more tolerant to lapatinib than parental cells [Figures 7 (H1650) and 7B (H1299)].

Figure 8: Gefitinib Sensitivity of gefitinib Tolerant Cells
(A) Gefitinib sensitivity in parental and gefitinib DT cell lines. H1299 (N=5) cells were
treated the day after seeding, in duplicates, with varying concentrations of the
gefitinib for 48 hours. Cell viability was determined using Cell Titer Glo assay
(Promega) according to the manufactures' protocol. Average IC50 value is shown
(B). Statistical significance for each experiment was determined using an un-paired
T-Test comparing each parental cell line to the corresponding DT cell line, * =
p<0.05, ** = p<0.005, *** = p<0.0005.
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H1975 and LLC DT cells showed only a modest increase in tolerance to lapatinib, less
than 2-fold, compared to their respective parental cells [Figures 7C (H1975) and 7D
(LLC)]. However, in all cell lines, the increase in lapatinib tolerance was statistically
significant (Figure 7E). H1299 gefitinib DT cells also showed only a marginal increase in
tolerance to gefitinib, less than 2-fold, compared to parental cells (Figure 8A). However,
this increase in gefitinib tolerance was significantly significant (Figure 8B).
We next used flow cytometry to perform an Annexin V apoptosis assay (BD
Biosciences), comparing the lapatinib tolerance of parental vs DT cells. This assay uses
fluorescent Annexin V, which is a Ca2+ dependent phospholipid-binding protein attached
to FITC dye, to detect phosphatidylserine (PS), which flips from the cytosolic side of the
cell membrane to the external side in apoptotic cells [57]. Movement of PS to the external
side of the cell membrane also occurs during cell necrosis, however during the early
stages of apoptosis the cell membrane remains intact, but it does not during necrosis [57].
Annexin V staining is usually performed along with a dye exclusion test to determine
integrity of the cell membrane [57]. PI is a fluorescent, DNA intercalating agent that can
be used to evaluate cell viability because it cannot cross the cell membrane of live cells
[57]. After staining with both probes, early-apoptotic cells show FITC+/PI-, late-apoptotic
or dead cells show FITC+/PI+, live cells show FITC-/PI-, and necrotic cells show FITC-/PI+.
When H1975 parental and lapatinib DT cells were exposed to 20 M lapatinib for 48 hours
we found that the percentage early apoptotic, annexin V positive cells was about 60% in
the parental cells compared to only 11% in the DT cells (Figure 9A). The percentage of
late apoptotic or dead cells was 20% in the parental cells compared to 10% in the DT
cells (Figure 7A). The total percentage of apoptotic cells in the parental group was about
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70% compared to just 31% in the DT cells. When H1299 parental and lapatinib DT cells
were exposed to 20 M lapatinib for 48 hours we found that no change in the percentage
of early apoptotic, annexin V positive cells (Figure 9B). However, the percentage of late
apoptotic or dead was 20% in the parental cells compared to only 6% in DT cells (Figure
9A). The total percentage of apoptotic cells in the parental group was about 21%
compared to just 7.5% in the DT cells.

Figure 9: Induction of Apoptosis by Lapatinib in Parental and Lapatinib
Tolerant Cell Lines
Annexin V/PI staining of parental and DT cells after exposure to lapatinib. Cells
were treated the day after seeding with indicated concentrations of the identified
drug for 48 hours. Cells were collected and then were stained for Annexin V and
PI using the BD Pharmingen FITC Annexin V Apoptosis Detection Kit I according
to the manufactures' protocol and assayed by flow cytometry. A) Parental and DT
H1975; B) Parental and DT H1299 cells. Graphs were derived using FloJo
software. (N=2).

We then used monolayer IC50 analysis, as described above, to determine the
sensitivity of our parental and lapatinib DT cell lines (H1650, H1299, H1975, and LLC) to
a panel of other FDA approved cancer therapeutics. We tested sensitivity of the cells to
50

Figure 10: Treatment of Lapatinib Tolerant Cells with Gefitinib
Gefitinib sensitivity in parental and lapatinib DT cell lines. H1650 (A), H1299 (B),
H1975 (C), and LLC (D) cells were treated the day after seeding, in duplicates, with
varying concentrations of the gefitinib for 48 hours. Cell viability was determined
using Cell Titer Glo assay (Promega) according to the manufactures' protocol.
Average IC50 value is shown (E) (N=2). Statistical significance for each experiment
was determined using an un-paired T-Test comparing each parental cell line to the
corresponding DT cell line, * = p<0.05.

other EGFR inhibitors (gefitinib and osimertinib), as well as a lung cancer standard of
care chemotherapeutic, gemcitabine. We found that H1650 and H1299 lapatinib DT cells
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had a slight tolerance to gefitinib, less than 1.5-fold, compared to parental cells [Figures
10A (H1650) and 10B (H1299)]. Both H1975 and LLC lapatinib DT cells showed no
increase in gefitinib tolerance compared to parental cells [Figure 10C (H1975) and 10D
(LLC)]. No lapatinib DT cell lines showed a statistically significant increase in gefitinib

Figure 11: Treatment of Lapatinib Tolerant Cells with Osimertinib
Osimertinib sensitivity in parental and lapatinib DT cell lines. H1299 (A), H1975 (B),
and LLC (C) cells were treated the day after seeding, in duplicates, with varying
concentrations of the osimertinib for 48 hours. Cell viability was determined using
Cell Titer Glo assay (Promega) according to the manufactures' protocol. Average IC50
value is shown (D) (N=2). Statistical significance for each experiment was
determined using an un-paired T-Test comparing each parental cell line to the
corresponding DT cell line, * = p<0.05.
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(Figure 10E). H1299, H1975, and LLC lapatinib DT cells showed no tolerance to
osimertinib compared to parental cells [Figures 11A (H1299), 11B (H1975), and 11C
(LLC)]. We found no statistically significant differences in the osimertinib tolerance of
H1299, H1975, or LLC lapatinib DT cells compared to parental cells (Figure 11D). We
found no increase in gemcitabine tolerance in H1650 lapatinib DT cells compared to
parental cells (Figure 12A). However, H1975 lapatinib DT cells showed almost a 2-fold
increase in gemcitabine tolerance compared to parental cells (Figure 12B). Neither
lapatinib DT cell line showed a statistically significant difference in gemcitabine tolerance
compared to parental cells (Figure 12C).

Figure 12: Treatment of Lapatinib Tolerant Cells with Gemcitabine
Gemcitabine sensitivity in parental and lapatinib DT cell lines. H1650 (A) and H1975
(B) cells were treated the day after seeding, in duplicates, with varying concentrations
of the gemcitabine for 48 hours. Cell viability was determined using Cell Titer Glo
assay (Promega) according to the manufactures' protocol. Average IC50 value is
shown (C) (N=2). Statistical significance for each experiment was determined using
an un-paired T-Test comparing each parental cell line to the corresponding DT cell
line, * = p<0.05.
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After testing the drug tolerance of our DT cells in monolayer cultures we next
repeated this test using our FiSS platform. To perform IC50 analysis on the FiSS we plated
parental and DT H1650 cells and allowed them to grow for 5 days to form tumoroids
[Figures 13A (Parental) and 13B (DT)]. Once the cells had formed tumoroids, varying
doses of lapatinib (2.5-160uM) were added. Cell Titer Glo was performed, as described
above, 48 hours later. Calculation of the IC50 value for each cell line was performed using
GraphPad Prism as described for monolayer analysis. As with monolayer culture, we
observed about a 2-fold greater lapatinib tolerance between DT cells compared to
parental cells (Figure 13C). We also found that the tolerance to lapatinib was significantly
increased, about 3-fold, when both parental and DT cells were cultured on our FiSS
compared to monolayer (Figure 13E).
We also examined lapatinib sensitivity in FiSS tumor biopsy cultures of parental
and DT cells. To perform this analysis, 3 million H1650 parental and DT cells were
injected subcutaneously into the flanks of mice. Parental cells were injected into the right
flank and DT cells were injected into the left flank. The tumors were allowed to grow until
they reached about 1000 mm3 or 10cm X 10cm. Tumors were then harvested and
digested to a single cell suspension using a mouse tumor digestion kit (Miltenyi Biotech).
Cells were then counted and plated on the FiSS platform. IC50 analysis was then
performed as described above for the FiSS platform. Instead of a 2-fold difference in
lapatinib tolerance between parental and DT cells as seen in both monolayer and FiSS
culture, we observed about a 4-fold difference in lapatinib tolerance between parental and
DT tumor biopsies cultured on the FiSS (Figure 13D). Tolerance to lapatinib increased,
about 3-fold, in both H1650 parental and DT cells, when cells were cultured from tumor
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Figure 13: Characterization of Lapatinib Tolerant Cells on FiSS
A-B) H1650-Par (A) and -DT (B) cell line grown on the FiSS (100X). C-D) A
comparison of drug sensitivity in parental and lapatinib DT H1650 cell lines cultured on
monolayer vs. FiSS. Monolayer (C) drug sensitivity experiments were performed as
described above. For FiSS (D) drug sensitivity experiments cells were treated on day 5
after seeding, in triplicates, with varying concentrations of the identified drug for 48
hours. Average IC50 value ±SEM in drug treated cultures on monolayer (N=5) and the
FiSS (N=5) is shown (E). (F) Lapatinib sensitivity in tumor derived biopsy cultures.
Drug sensitivity experiments were performed as described previously for the FiSS.
Average IC50 value ±SEM in drug treated cultures on the FiSS (N=5) and biopsy
cultures on the FiSS (N=4) is shown. Statistical significance for each experiment was
determined using an un-paired T-Test comparing each parental cell line to the
corresponding DT cell line, * = p<0.05, ** = p<0.005, *** = p<0.0005.

biopsies on the FiSS as compared to the cell line alone cultured on the FiSS (Figure 13F).
These results suggest that lapatinib resistance can be enhanced by the FiSS and further
enhanced when cultured from tumor biopsies on FiSS.
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We next used the capillary electrophoresis and western blotting system, WES
(Protein Simple) to examine the status of EGFR pathway signaling in both parental and
DT cells. In the Wes immunoassay method, protein separation, primary and HRPconjugated secondary antibody incubation, as well as detection happens with a small
disposable capillary tube in the instrument [58]. Within the Compass software (Protein
Simple) one can view the chemiluminescent signal displayed as an electropherogram or
a virtual blot-like image [59]. Using the electropherogram, detected peaks can be
quantified by calculation of the area under the curve (AUC) [59]. We isolated protein from
both parental and DT H1650 cells using RIPA buffer and quantified the concentration
using Coomassie protein assay kit (Thermo Fisher Scientific). Running the samples in
triplicate, we then used WES to determine the relative levels of EGFR, phospho-EGFR,
AKT, phosphor-AKT, ERK, and phosphor-ERK (Figure 14A). While total EGFR remained
steady between the two cell lines, a significant decrease was seen in total AKT and ERK
protein, as well as phospho- AKT, ERK, and EGFR (Figure 14B and 14C). Overall, EGFR
pathway downstream signaling was shown to be downregulated in H1650 DT cells
compared to parental.
We next conducted mass spectrometry using Isobaric tags for relative and
absolute quantitation (ITRAQ) labeling and analysis to find alterations in the proteome of
parental vs. DT cells. ITRAQ uses stable isotope labeled molecules that can be covalent
bonded to the N-terminus and side chain amines of peptides with tags of varying mass
[60]. All of the peptides from a single sample are labeled with a tag of specific mass. Once
labeled with separate tags the different samples can then be pooled and analyzed using
mass spectrometry. The attached tag generates a low molecular mass reporter ion that
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Figure 14: Analysis of EGFR Pathway in Parental vs Lapatinib Tolerant Cells
(A-C) EGFR pathway signaling protein expression in H1650 parental and lapatinib
DT cells. WES automated capillary western blotting of whole cell lysate using
antibodies against the indicated proteins. (A) The expression of proteins was
determined using area under the curve (AUC) measurements generated using
Compass software for Simple Western (Protein Simple). (B) Average normalized
fold change ±SEM of EGFR (N=2), AKT (N=3), and ERK (N=3) compared to
parental, is shown. β-actin was used as a loading control to normalize AUC
measurements. (C) Average % of normalized total protein ±SEM expression of
pEGFR (N=2), pAKT (N=3), and pERK (N=3) is shown. Each phospho-protein was
graphed as a percent of the respective total protein. Statistical significance for each
experiment was determined using an un-paired T-Test comparing protein level for
the parental cell line to the corresponding DT cell line, * = p<0.05, ** = p<0.005, ***
= p<0.0005.
is used to relatively quantify the peptides from the different samples. It should be noted
however, data analysis techniques for iTRAQ often struggle to report reliable relative
protein abundance estimates, as accuracy is compromised, and ratios are compressed
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toward 1, often leading to underestimation of the ratio [61]. Even with this limitation, we
found over 500 different proteins that are significantly differentially expressed in DT cells
compared to parental cultures.

Table 7: Selected proteins upregulated in lapatinib DT
H1975 lung cancer cells compared to the parental cells
Altered Proteins

Fold Change

Mann-Whitney
Test (p-value)

CYP51A1

2.11

0.021

YWHAH

1.99

0.00088

CPT1A

1.39

0.021

MIC60

1.30

<0.0001

SOAT1

2.09

0.021

We performed a PubMed search of the published literature of some of the top differentially
expressed genes. Table 7 lists top protein candidates that were upregulated in the DT
cells compared to the parental cells. The protein Cytochrome P450 CYP51A1, which is
directly involved with cholesterol synthesis, was up-regulated in DT cells compared to the
parental cells [62]. The protein 14-3-3 (YWHAH), which is a scaffolding protein known to
function in a wide variety of cellular processes was also upregulated in DT cells [63-65].
We found that carnitine palmitoyltransferase (CPT1A), a mitochondrial enzyme that
facilitates lipid catabolism is significantly up regulated in the H1975 DT cells [66, 67].
Also upregulated in the DT cells was the enzyme, sterol O-acyltransferase 1 (SOAT1), a
key enzyme converting endoplasmic reticulum cholesterol to cholesterol esters [68].
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4.3 Discussion
Many of the reported EGFR TKI resistance studies use cell models that are allowed to
acquire resistance over a long period of chronic exposure to the compound, usually at
escalating dosing concentrations [69]. In this study, we aimed to investigate the "early"
molecular events that are responsible for acquired resistance to EGFR TKIs. To this aim,
we developed a model in which we drugged the untreated or parental cells with the
highest concentration of the respective EGFR TKI that would still allow for proliferation
and constantly exposed the cells to this concentration throughout the study. This allowed
outgrowth of the EGFR TKI tolerant (DT) cells that were able to survive the initial insult of
the EGFR TKI and grow in its presence. Further study of this cell population would allow
us to examine mechanisms contributing to cellular survival in response to EGFR
inhibition.
IC50 analysis was then performed to determine if exposure to an EGFR TKI would
cause any change in the sensitivity of the cells to that EGFR TKI compared to cells not
previously exposed. We found that in H1299 and H1650 cells exposed to lapatinib, the
DT cells had a 2-fold greater tolerance for lapatinib than their respective parental cells. In
H1975 and LLC cells we observed only a modest increase in lapatinib tolerance of the
DT cells compared to parental cells. H1299 cells exposed to gefitinib showed a marginal
increase in gefitinib tolerance. We then incorporated cell culture on our FiSS to validate
any findings of DT cells grow on traditional 2D monolayer. Two-dimensional (2D) cultures
are severely limited in their ability to mimic the 3D environment of the tumor
microenvironment. We are also able to use the FiSS to grow tumor biopsies. These tumor
biopsies contain not only the cancer cells, but also the stromal cells which allow for a
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more in vivo like environment. These FiSS tumor biopsy cultures have been shown to
support the growth of cancer associated fibroblasts (CAFs) and endothelial cells (ECs),
as well as the cancer cells [56]. I tested the EGFR TKI sensitivity of parental and DT cells
on the FiSS and FiSS biopsy cultures. Using these culture systems, we obtained a trend
similar to EGFR TKI DT cells when grown on a 2D monolayer. This provides us with
evidence that the acquisition of EGFR TKI drug tolerance is not just a phenomenon of the
2D monolayer culture system.
To determine if this increase in lapatinib tolerance of DT cells was due to
downstream signaling through the EGFR pathway, we used the WES (Protein Simple)
capillary immunoassay system to examine proteins involved in EGFR pathway signaling.
We found that although total EGFR protein was unchanged between H1650 parental and
DT cells, phosphor-EGFR, AKT, phosphor-AKT, ERK, and phosphor-ERK were all
downregulated in DT cells compared to parental. This is most likely since DT cells are
grown in the presence of the EGFR TKI lapatinib, which would cause this effect by
inhibiting EGFR and thus lowering downstream signaling through the EGFR receptor.
Since EGFR signaling does not seem to be causing the drug tolerant state in these
cells, we next performed mass spectroscopy with ITRAQ labeling to probe the entire
proteome of H1975 parental vs DT cells to help us figure out which cellular mechanisms
may be leading to the EGFR TKI tolerant phenotype. Analysis of the significantly
differentially expressed proteins list generated by the mass spectroscopic analysis
revealed that the protein expression is skewed in lapatinib DT cells as compared to
parental.
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We used a PubMed search of the published literature to search for information
related to EGFR, TKIs, drug resistance, and our identified proteins of interest from the
differential expressed protein list, which were significantly upregulated in DT cells.
CYP51A1, which is directly involved with cholesterol synthesis, has never been implicated
in EGFR TKI resistance, however cholesterol has been shown to play a role in resistance
to EGFR TKIs [70]. The protein 14-3-3, which is a scaffolding protein known to function
in cell-cycle progression, apoptosis and mitogenic signaling, has been implicated to play
a role in regulation of proteins that are important to both cancer growth and drug
resistance [64, 65]. Lipid metabolism is known to be up regulated in lung cancer and aid
in cancer progression [71, 72]. In line with this, CPT1A, is a mitochondrial enzyme that
facilitates lipid catabolism and has been implicated in breast cancer cell survival and
invasion [66, 67]. SOAT1, an enzyme that converts cholesterol to cholesterol esters,
functions to store cholesterol in lipid droplets and its inhibition has been shown to
suppress glioblastoma growth through blocking of sterol regulatory binding protein 1
(SREBP1) mediated lipogenesis [68].
Three of these proteins, CYP51A1, SOAT1, and CPT1A, function in pathways that
metabolize lipids and cholesterol. It has been shown that statins, which work to lower
cholesterol, in combination with EGFR TKIs have been shown to provide additional
benefits over EGFR TKIs alone, both in vitro and in vivo [73, 74]. Ming-Szu Hung et. al.
conducted a population-based case-control study, including 1,707 statin and 6,828 nonstatin matched lung cancer cohorts with EGFR TKI treatment, and found that statin use
was associated with a reduced risk of death, a significantly longer median progressionfree survival, and significantly longer median overall survival [73]. Due to this encouraging
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clinical knowledge of EGFR TKIs in combination with statins and the fact that the role of
CYP51A1 and cholesterol in EGFR TKI resistance is not fully understood, we chose to
continue our study down this path.
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CHAPTER 5:
CHOLESTEROL, EGFR TKI DT, AND APOPTOSIS

5.1

Introduction

Cytochrome P450 CYP51A1 or lanosterol 14a-demethylase, lies between HMGCR and
DHCR7 or DHCR24 enzymes in the cholesterol biosynthesis pathway (Figure 16).
CYP51A1 is the most evolutionarily-conserved member of the cytochrome P450
superfamily and in humans it converts lanosterol to FF-MAS (4,4-dimethyl-5alphacholesta-8,14,24-triene-3beta-ol) and 24,25-dihydrolanosterol to dihydro-FF-MAS [75].
The lipid cholesterol plays important roles in maintaining cellular homeostasis, with its
varying roles ranging from, it being a precursor for steroid hormones, being an essential
component of plasma membranes and lipid rafts, and also playing a key role in
intracellular signal transduction [76, 77]. The liver is the primary site of cholesterol
synthesis, it is then transported in a bound complex with protein, as a low-density
lipoprotein (LDL), to cells throughout the body [76, 77]. Cholesterol is then taken into cells
and packaged into lysosomes, where it is separated from the LDL protein complex into
free cholesterol, which is then transported to the cell membrane and membrane–bound
organelles [76, 77].
Sterol regulatory element binding proteins (SREBPs) and liver X receptors (LXR)
act as master regulators of a cholesterol homeostasis network, which involves import,
synthesis, export, metabolism, and esterification [76, 77]. Endoplasmic reticulum (ER)
cholesterol levels control cellular cholesterol levels through a sensor type mechanism.
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When a decrease in ER cholesterol is detected it causes translocation of SREBPs into
the nucleus and subsequent activation of its target genes involved in cholesterol synthesis
and uptake, whereas when increased ER cholesterol is detected it causes a decrease in
cholesterol synthesis and activation of cholesterol export through LXR receptors [76, 77].

Figure 15: Pathway of Cholesterol Synthesis
Acetyl-CoA is first converted into HMG-CoA and then into mevalonate. This is then
converted into squalene, followed by lanosterol, which is further converted into
zymosterol and zymostenol. These are finally converted into cholesterol.
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All cells of the body that contain a nucleus are capable of synthesizing cholesterol from
acetyl CoA through the mevalonate pathway, primarily in the ER [78] (Figure 15). AcetylCoA is first converted into HMG-CoA and then into mevalonate by HMG-CoA reductase
(HMGCR), which is the rate-limiting step of this pathway [78]. The next few steps convert
mevalonate into squalene and then into the first sterol intermediate, lanosterol, by
squalene monooxygenase (SQLE) and Lanosterol synthase (LSS) [78]. Lanosterol is
converted into zymosterol and zymostenol through a series of reactions by the enzymes,
Lanosterol 14-Alpha Demethylase (CYP51A1), Delta(14)-sterol reductase (DHCR14),
and 24-Dehydrocholesterol Reductase (DHCR24) [78]. These are then converted into
cholesterol through a series of reactions y the enzymes, Delta(8)-Delta(7) sterol
isomerase (Ebp), Lathosterol oxidase (SC5D), 7-dehydrocholesterol reductase (DHCR7),
and DHCR24 [78].
Most of the de novo synthesized cholesterol, as well as its sterol precursors,
zymosterol, lathosterol and desmosterol, exit the ER quickly in order to maintain a low ER
sterol content [76]. Cholesterol is then distributed between various cellular membranes in
a non-equal manner, as it is enriched in the plasma membrane, accounting for 20–25%
of the all lipid molecules, with phospholipids, sphingomyelin and glycolipids accounting
for the remaining 75-80% [76]. Cholesterol is made up of a unique puckered four-ring
structure that causes an increase in cohesion and packing of lipids in its vicinity [76].
When cholesterol is close to saturated hydrocarbon chains they lose flexibility, causing
increased lateral ordering, which decreases membrane fluidity, and affects the
biophysical properties of the cell membrane [76].
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Upregulation of cholesterol synthesis in cancer has been shown to correlate with
poor prognosis in patients and plays a role in the development of drug resistance, as
overexpression of cholesterol pathway genes has been observed in refractory tumors [77,
79, 80]. In cancer cells, increased signaling of PI3K/AKT/mTOR, MAPK/ ERK1/2, and
TP53 pathways have been implicated in the activation of SREBPs [77, 79] (Figure 16).

Figure 16: EGFR Signaling and Cholesterol Metabolism
EGFR pathway signaling leads to activation of SREBP1 and SREBP2 transcition
factors, which turn on genes associated with fatty acid and cholesterol synthesis.

One place where excess cholesterol could be playing a major role is the development
and functioning of lipid rafts. Lipid rafts are small domains within the cell membrane that
are less fluid than the neighboring membrane due to the fact that they are enriched in
cholesterol and sphingolipids and they are grouped into two distinct forms: planar non-
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caveolar and caveolae that form tube-like invaginations of plasma membrane [79, 81].
Lipid rafts are thought to function mainly as signaling centers where numerous proteins,
including receptors and signaling molecules, will congregate to improve signaling
efficiency [81, 82]. Due to their involvement with many signaling centers, such as growth
factor receptors including EGFR, lipid rafts have shown to be important components of
cellular signaling processes, such as cell growth and proliferation, apoptosis, and
migration [81, 82]. The involvement of lipid rafts in the development and progression of
carcinogenesis has been shown in several tumor models, such as breast, colon, lung and
prostate cancers [81, 82].
EGFR has been shown in multiple studies to be associated with lipid rafts [79, 81,
83]. Specifically, endocytosis is thought of as the mechanism for cholesterol regulation of
EGFR signaling, as after engagement of the EGFR with its ligands, it can be internalized
through two main pathways: clathrin-dependent and clathrin-independent [79, 81, 83].
The signaling activity, stability, and availability of EGFR is governed by its endocytic
routes and the choice between these two routes seems to be dependent on ligand
concentration [79, 81, 83]. Under low ligand stimulation EGFR is predominantly
internalized through clathrin dependent vesicles and under high ligand concentration
EGFR internalization is equally distributed between clathrin and non-clathrin dependent
vesicles [79, 81, 83]. Clathrin-dependent endocytic EGFR trafficking is linked to EGFR
recycling,

whereas

clathrin-independent

endocytic

trafficking

promotes

EGFR

degradation [79, 81, 83]. In fact, the sub-cellular localization of EGFR has even been
shown to determine the downstream pathway activation, for example, EGFR localized in
endosomes causes activation of the ERK/MAPK pathway, whereas mitochondrial
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localized EGFR has been shown to modify cytochrome c oxidase subunit II activity, and
finally localization of EGFR to the cell membrane results in classical stimulation of both
MAPK and Akt signaling pathways [70]. While lipid raft localization of EGFR has been
extensively studied, conflicting results have been obtained, as some studies show
localization inhibits ligand binding and downstream signaling, and other studies show
localization promotes EGFR signaling [70]. It is clear that more research needs to be done
in this area to determine the specific biological processes that govern the downstream
effects of EGFR localization to lipid rafts.
In the case of EGFR TKI activity, a few studies have been done to determine to
role of lipid rafts in the cellular responses to EGFR inhibition by TKIs [70, 84]. Qiufang
Chen et. al. found that cholesterol level in lipid rafts in gefitinib resistant NSCLC cell lines
was significantly higher than a gefitinib sensitive cell line [84]. While Mary E. Irwin et. al.
found that EGFR localized to cell membrane lipid rafts in EGFR TKI resistant cell lines,
and that the lipid rafts were providing a platform for activation of Akt signaling even in the
absence of EGFR kinase activity [70]. These studies highlight the potential role that lipid
rafts, which are enriched in cholesterol, may be playing in the acquisition of EGFR TKI
resistance, however more studies need to be performed to determine the exact roles
these lipid rafts, along with cholesterol, are playing in acquired EGFR TKI resistance.
Another potential role for cholesterol modulation of the EGFR pathway lies in the
mitochondrial membrane and its role in apoptosis. In some cancers enriched
mitochondrial cholesterol levels have been shown to induce resistance to apoptotic
signals [85-87]. Several studies have shown that elevated levels of mitochondrial
cholesterol in cancer cells may be able to protect cancer cells against mitochondrial
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apoptosis due to changes in mitochondrial membrane dynamics and permeability, which
[85-87]. In these cases, a cholesterol-mediated decrease in mitochondrial membrane
fluidity reduces the ability of BAX to insert into the mitochondrial membrane and impairs
mitochondrial outer membrane permeabilization (MOMP) and the release of cytochrome

c in response to BAX [85-87]. So far however, no studies have linked this phenomenon
to EGFR TKI exposure and resistance.

Figure 17: EGFR TKIs, Mitochondrial Cholesterol, and Apoptosis
Upregulation of cholesterol is leading to enriched cholesterol levels within the
mitochondrial membrane and playing an anti-apoptotic role to prevent MOMP and
release of cytochrome C, thus allowing the cells to survive exposure to EGFR TKIs.
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Since we have already shown that the EGFR pathway is downregulated in H1650
lapatinib DT cells in chapter 4 and an increase in lipid raft signaling caused by increased
cholesterol would theoretically function to turn on the EGFR pathway in DT cells, we do
not think that EGFR pathway activation is responsible for the increased EGFR TKI
tolerance in our DT model. We then hypothesized that upregulation of CYP51A1 is
leading to an increase in cellular cholesterol in EGFR TKI DT cells and this is causing
enriched cholesterol levels within the mitochondrial membrane and playing an antiapoptotic role to prevent MOMP and release of cytochrome C, thus allowing the cells to
survive exposure to EGFR TKIs (Figure 17). This work is innovative because it will further
explore the role of cholesterol in EGFR TKI resistance, adding to the small numbers of
studies currently performed, and for the first time study the role of mitochondrial
cholesterol in EGFR TKI resistance.

5.2

Results

After finding an upregulation of CYP51A1 in EGFR TKI DT cells in chapter 4, we next
examined whether this upregulation would lead to an increase in total cellular cholesterol
and the roles enriched cholesterol levels could play in relation to EGFR TKI tolerance in
our cell models. Differences in cholesterol synthesis between parental and DT cells were
studied using a variety of techniques including qPCR, western blotting, and cellular
cholesterol assays. First, we examined the weather exposure to lapatinib or gefitinib
would cause upregulation of cholesterol in parental cells. H1299 cells were exposed to
7.5M of lapatinib or 15 of gefitinib for up to 14 days, these are the same concentrations
that the cells are grown in to make them EGFR TKI DT. Cells were collected, and
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cholesterol was extracted when cells reached 90% confluency by using a 30:20 solution
of Hexane/Isopropanol. Total cellular cholesterol was then determined using the Amplex
Red Cholesterol Assay Kit (Thermo Fisher Scientific). The Amplex Red cholesterol assay
uses an enzyme-coupled reaction to produce fluorescent resorufin from the reaction of
the Amplex Red reagent with H2O2, which is produced from the cholesterol oxidase-

Figure 18: Cholesterol Metabolism is Upregulated in Parental Cells Following
Exposure to EGFR TKIs
Cholesterol content of EGFR TKI treated parental cells. H1299 cells were treated at
seeding with 7.5M lapatinib or 15M gefitinib for the indicated number of days. Average
fold change ±SEM, compared to untreated, is shown [Parental (N=10), LP Day 3 (N=6),
LP day 14 (N=2), Gef Day 3 (N=6), Gef Day 14 (N=4)]. Statistical significance for each
experiment was determined using an ANOVA and the Tukey post hoc test, * = p<0.05, **
= p<0.005, *** = p<0.0005 compared to untreated, # = p<0.05, ## = p<0.005, ### =
p<0.0005 comparing the two groups connect by the line.

catalyzed oxidation of cholesterol. The assay detects both free cholesterol and cholesteryl
esters. The fluorescent product was measured using a fluorescent plate reader and
cholesterol content was determined using a known standard curve. Average cholesterol
content as a percentage of control in drug treated cultures was then calculated.
Cholesterol content was normalized to untreated cells using cell count. Total cellular
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cholesterol was found to be
upregulated in parental cells
treated

with

lapatinib

by

about 2.5-fold compared to
untreated at 3 days (Figure
18).

However,

total

cholesterol reduced slightly
during 14 days of lapatinib
Figure 19: Upregulation of Cholesterol
Metabolism Enzymes in Parental Cells Following
Exposure to EGFR TKIs
Gene expression in EGFR TKI treated parental cells.
H1299 (N=3) cells were treated at seeding with
7.5µM lapatinib or 20µM gefitinib for 14 days.
Average fold change ±SEM, compared to untreated,
is shown. Statistical significance for each experiment
was determined using an un-paired T-Test comparing
each mRNA level for the parental cell line to the
corresponding DT cell line, * = p<0.05, ** = p<0.005,
*** = p<0.0005.

exposure but remained about
1.5-fold

greater

than

untreated cells (Figure 18).
Total cellular cholesterol was
also found to be upregulated
in

H1299

parental

cells

treated with gefitinib by about

3.5-fold compared to untreated at 3 days (Figure 18). However, total cholesterol reduced
slightly during 14 days of lapatinib exposure but remained about 2-fold greater than
untreated cells (Figure 18).
We next looked at enzymes involved in cholesterol synthesis, such as CYP51A1,
DHCR7, DHCR24, and LSS, as well as the transcription factor SREBF2 to determine if
they were responsible for the upregulation in cholesterol. After exposing H1299 cells to
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lapatinib or gefitinib for 14 days we collected
the cells and extracted mRNA to determine
the level of expression of cholesterol
synthesis genes. After exposure to 7.5M
lapatinib, H1299 cells showed an increase of
at least 2-fold in CYP51A1, DHCR7, and
DHCR24, as well as a >20-fold increase in
Figure 20: Upregulation of Cholesterol
Metabolism in Parental Cells Following
Exposure to Established Cancer Therapies

SREBF2

(Figure

19).

After

H1650 cells were treated at seeding with the
indicated drug for 48 hours. Average cholesterol
content as a percentage of control in drug treated
cultures is shown (N=2). Cholesterol content was
normalized to untreated cells using cell count.
Statistical significance for each experiment was
determined using an ANOVA and the Tukey post
hoc test, * = p<0.05, ** = p<0.005, *** = p<0.0005
compared to untreated.

showed an increase of at least 2-

exposure to 15M gefitinib, H1299

fold in CYP51A1, DHCR7, and
DHCR24, as well as a >20-fold
increase in SREBF2 (Figure 19).
Not only did we check the
upregulation of cholesterol after

exposure to EGFR TKIs, but also after treatment with the chemotherapeutics,
gemcitabine and cisplatin, which are standards of care in lung cancer. After 48 hours of
exposure to the drugs, H1650 cells were collected and cholesterol was extracted using a
30:20 solution of Hexane/Isopropanol. Total cellular cholesterol was then determined
using the Amplex Red Cholesterol Assay Kit (Thermo Fisher Scientific). Average
cholesterol content as a percentage of control in drug treated cultures was then
calculated. Cholesterol content was normalized to untreated cells using cell count. We
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found that both 7.5M of lapatinib and 15M of
gefitinib

significantly

increased

total

cellular

cholesterol about 2-fold compared to untreated cells
(Figure 20). However, exposure to 1M gemcitabine
and 40M cisplatin did not significantly increase total
cellular cholesterol (Figure 20).
We next looked at cellular cholesterol levels
Figure 21: Cholesterol is
Upregulated in EGFR TKI Tolerant
Cells

in both lapatinib and gefitinib DT cells.

Cholesterol content of lapatinib DT
and gefitinib DT cells. Average fold
change ±SEM, compared to parental,
is shown [H1299 (N=10), H1299 DT
(N=6), H1650 (N=6), H1650 DT (N=6),
H1975 (N=14), H1975 DT (N=14),
LLC (N=4), LLC DT (N=4), H1299
(N=8), H1299 Gef DT (N=6)].
Statistical significance for each
experiment was determined using an
un-paired T-Test comparing the
parental cell line to the corresponding
DT cell line, * = p<0.05, ** = p<0.005,
*** = p<0.0005.

using

Cholesterol was extracted from cell pellets
a

30:20

Hexane/Isopropanol.

solution
Total

of
cellular

cholesterol was then determined using the
Amplex Red Cholesterol Assay Kit (Thermo
Fisher

Scientific).

Average

cholesterol

content as a percentage of control in drug
treated

cultures

Cholesterol

was

content

then

was

calculated.

normalized

to

untreated cells using cell count. As with
parental cells exposed to EGFR TKIs, H1299, H1650, H1975, and LLC lapatinib DT cells
show a significant
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Figure 22: Upregulation of Cholesterol Metabolism Enzymes in EGFR TKI
Tolerant Cells
Gene expression in EGFR TKI DT cells. Average fold change ±SEM, compared to
parental, is shown [H1299 LP (N=9), H1975 LP (CYP51A1 N=6) (DHCR7 N=6)
(DHCR24 N=9) (SREBP2 N=9), H1650 LP (N=6), H1299 Gef (N=3)]. Statistical
significance for each experiment was determined using an un-paired T-Test
comparing each mRNA level for the parental cell line to the corresponding DT cell
line, * = p<0.05, ** = p<0.005, *** = p<0.0005.

upregulation of cholesterol, 1.5-2-fold, compared to their parental cells (Figure 21). We
also found a significant increase in total cellular cholesterol in H1299 gefitinib DT cells of
about 1.5-fold compared to parental cells (Figure 21). We next looked at mRNA transcript
and protein levels of enzymes involved in cholesterol synthesis, such as CYP51A1,
DHCR7, DHCR24, and LSS, as well as the transcription factor SREBF2, in DT vs parental
cells. All the cell lines show between a 2.5- and 5-fold increase in these genes, besides
H1975, which also show about a 7.5-fold increase in DHCR24, and H1299 Gefitinib DT,
which show about a 12.5-fold increase in SREBF2 (Figure 22).
We then used the WES (Protein Simple) capillary immunoassay system to
examine protein levels of cholesterol synthesis enzymes in H1975 parental and DT cells
(Figure 23A). Using AUC analysis, we found a 2-fold increase in CYP51A1 protein levels
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in

DT

cells

compared

to

parental (Figure 23B). In both
DHCR24 we saw a 1.5-fold
increase in DT cells compared
to parental (Figures 23B).
SREBP2 only showed a slight,
1.25-fold, increase in DT cells
compared to parental (Figure
23B).
We next asked, is the
cholesterol being loaded into
Figure 23: Upregulation of Cholesterol
Metabolism Enzymes in H1975 Lapatinib DT Cells
(A-B) Cholesterol synthesis enzyme protein
expression in H1975 parental and lapatinib DT cells.
(A) WES automated capillary western blotting of
whole cell lysate using antibodies against the
indicated proteins. (B) The expression of CYP51A1
(N=3), DHCR24 (N=3), and SREBP2 (N=3) was
determined using AUC measurements generated
using Compass software for Simple Western (Protein
Simple). α-actinin was used as a loading control to
normalize AUC measurements. Average normalized
fold change ±SEM, compared to parental, is shown. *
= p<0.05, ** = p<0.005, *** = P<0.0005.

the

mitochondrial

membranes?

H1650

H1975

pellets

cell

and
were

collected and mitochondria
were

extracted

using

the

Mitochondria Isolation Kit for
Cultured Cells (Thermo Fisher
Scientific). We used COX4 as
a mitochondrial marker and

vinculin as a cytoplasmic marker, to confirm proper isolation of mitochondria and
normalize loading (Figure 24A). Cholesterol was extracted from mitochondrial pellets
using a 30:20 solution of Hexane/Isopropanol. Total cellular cholesterol was then
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determined using the Amplex Red Cholesterol Assay Kit (Thermo Fisher Scientific).
Average cholesterol content as a percentage of control in drug treated cultures was then
calculated. Cholesterol content was normalized to untreated cells using cell count. In both
H1650 and H1975 DT cells we found that, just as total cellular cholesterol, mitochondrial
cholesterol
about

was

2-fold

upregulated

compared

to

parental (Figure 24B).
Lastly,

we

examined

what

happened when we withdrew
lapatinib from H1299 lapatinib
DT cell culture media for 20
Figure 24: Mitochondrial Cholesterol is Upregulated in
Lapatinib Tolerant Cells
A) Mitochondrial isolation in H1975 parental and lapatinib DT
cells. WES automated capillary western blotting of
mitochondrial isolate using antibodies against the indicated
proteins. B) Mitochondrial cholesterol content of lapatinib DT
cells. Average fold change ±SEM, compared to parental, is
shown [H1975 (N=4), H1975 DT (N=4), H1650 (N=2), H1650
DT (N=2)]. * = p<0.05, ** = p<0.01, *** = P<0.001, **** =
P<0.0001.

days. Cholesterol was
extracted

from

cell

pellets using a 30:20
solution

of

Hexane/Isopropanol.
Total

cellular

cholesterol was then
determined using the Amplex Red Cholesterol Assay Kit (Thermo Fisher Scientific).
Average cholesterol content as a percentage of control in drug treated cultures was then
calculated. Cholesterol content was normalized to untreated cells using cell count. We
found that even after a 20-day withdrawal of lapatinib from the culture media, H1299
lapatinib DT cells show a 5-fold higher level of cholesterol than parental cells (Figure
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25A). However, the level of cholesterol decreased to about 3 -fold compared to parental
cells (Figure 25A).
We then used WES (Protein Simple) capillary immunoassay system to examine
protein levels of the cholesterol synthesis enzymes, CYP51A1, LSS, and DHCR24, as
well as the transcription factor SREBF2 (Figure 25B). Using AUC analysis, we found a 2fold increase in CYP51A1 protein levels in DT cells compared to parental and a 1.5-fold

Figure 25: Withdrawal of Lapatinib from Lapatinib Tolerant Cells
A) Parental-, DT-, Lapatinib withdrawn DT- H1299 cell pellets. Average cholesterol
content as a percentage of control in drug treated cultures is shown. Cholesterol
content was normalized to parental using cell count (N=2). Statistical significance for
each experiment was determined using an ANOVA and the Tukey post hoc test, * =
p<0.05 compared to untreated. Calculations were performed and graphs produced
using Prism 6.0 software (GraphPad). B) The expression of CYP51A1 (C), DHCR24
(D), LSS (E), and SREBP2 (F) was determined using the WES (Protein Simple)
automated western blotting system. Alpha-actinin was used as a loading control. (C-F)
Analysis was performed using area under the curve measurements generated using
Compass software for Simple Western (Protein Simple). * = p<0.05, ** = p<0.01, *** =
P<0.001, **** = P<0.0001.
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increase in the DT cells withdrawn from lapatinib compared to parental (Figure 25C). We
also found a 1.5-fold increase in both DHCR24 and LSS in DT cells compared to parental
and about a 1.25-fold increase in the DT cells withdrawn from lapatinib compared to
parental [Figures 25D (DHCR24) and 25E (LSS)]. SREBP2 only showed a slight (1.25fold), increase in DT cells and DT cells withdrawn from lapatinib compared to parental
(Figure 25F).

5.3

Discussion

With CYP51A1 shown to be upregulated in EGFR TKI DT cells, we chose to investigate
the effect this is having on total cellular cholesterol levels and the role this cholesterol
could be playing in EGFR TKI DT cells. Our data shows that cells under exposure to
EGFR TKIs, whether it be short (72 hours) or longer (20-60 days), display an
upregulation in cholesterol synthesis enzymes, as well as total cellular cholesterol
levels. In both parental cells treated with EGFR TKIs and EGFR TKI DT cells we
observed an increase in total cellular cholesterol levels, as well as enzymes directly
involved in cholesterol synthesis. Once the EGFR TKI was withdrawn from the culture
media of the EGFR TKI DT cells, we saw a decline in the cellular cholesterol levels,
however they did remain increased compared to parental cells. The presence of the
EGFR TKI within the cells is keeping cholesterol synthesis upregulated and once the
drug is withdrawn, we see a decrease in the level of cholesterol synthesis.
We are not the first group to find cholesterol upregulation in EGFR TKI resistance
cells, as Quifang Chen et. al. have shown this in gefitinib resistant cells [84]. However,
from our literature searches, we are the first group to show upregulation of cholesterol
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synthesis in direct response to EGFR TKI exposure. In Quifang Chen et. al. the authors
were using cell lines with different sensitivities to gefitinib as a model of resistance. The
cells were not under exposure to gefitinib when cholesterol was isolated, but rather they
were comparing levels between the different cell lines.
We are also the first group to show that mitochondrial cholesterol levels are
upregulated in lung cancer cells exposed to EGFR TKIs. However, mitochondrial
cholesterol has been implicated in drug resistance to chemotherapy in hepatocellular
carcinoma by Joan Montero et. al. [86]. This data suggests that the extra cholesterol
present in the cells after exposure to EGFR TKIs is being trafficked to the mitochondrial
membrane. Taken all together, this data demonstrates the upregulation of mitochondrial
cholesterol in lung cancer cells after exposure to EGFR TKIs and provides a potential
target to overcome the development of EGFR TKI resistance.
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CHAPTER 6:
LAPATINIB AND KETOCONAZOLE COMBINATION THERAPY TO STOP THE
DEVELOPMENT OF EGFR TKI RESISTANCE

6.1

Introduction

Numerous cellular pathways have been implicated in EGFR TKI resistance and this has
led to idea that combination drug therapies targeting EGFR and a particular resistance
pathway would be a promising strategy to overcome EGFR TKI resistance [10]. A number
of studies have identified and targeted possible resistance mechanisms to circumvent
EGFR

TKI

resistance,

these

include

tyrosine

kinase

pathways

such

as,

PI3K//AKT/mTOR, Ras/Raf/Mek/ERk, JAK/STAT, Src, MET, VEGFR, FGFR, as well as
other targets such as, HSP90, HDAC, Hedge-hog (Hh), COX-2, and HMG-CoA [10, 15,
74, 88-98] (Figure 26).
Z Tang et. al. found that the MET signaling is activated in H1975 cells that express
the T790M EGFR mutation and that combination treatment with a MET inhibitor and
EGFR TKI may represent a strategy to overcome T790M mediated EGFR TKI resistance
[97]. Xiao-Yan Bai et. al. showed that upregulation of Hh signaling contributed to EGFRTKI resistance and blockade of Hh signaling sensitized EGFR TKI resistant cells to EGFR
TKI therapy [88]. Ji-Young Song et. al. discovered that combination treatment with a
MEK1/2 inhibitor and lapatinib is able to overcome EGFR TKI resistance through the
inhibition of ERK and the upregulation of BIM [96]. Malabika Sen et. al. used a STAT3
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inhibitor along with an EGFR TKI to significantly enhanced anti-tumor effects of EGFR
TKI treatment [95]. Collin M. Blakely et. al. unveiled NF-kB activation as a survival
mechanism upregulated by EGFR TKI treatment and that NF-kB inhibition along with
EGFR TKI treatment can overcome this resistance response [99]. Samuel W. Brady et.
al. indicated that lapatinib resistance is mediated through a p110a protein upregulation
and/or mutation-induced PI3K activation and that a combinatorial targeted therapy with a
p110a-specific PI3K inhibitor was able to overcome lapatinib resistance [89]. These
studies serve to highlight the potential of combination therapies to overcome the vast
number of resistance mechanisms cells can undergo after EGFR TKI treatment.

Figure 26: Combating EGFR TKI Resistance Mechanisms
To overcome EGFR TKI resistance, inhibitors of EGFR downstream signaling
proteins and parallel alternative tyrosine kinase receptors, as well as growth
factors receptors are used to block known resistance mechanisms.
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One potential combination therapy not highlight above is the potential use of statins
and other cholesterol synthesis inhibitors along with EGFR TKIs to overcome resistance.
Ki-Eun Hwang et. al. found that combination treatment of EGFR TKIs and simvastatin can
overcome T790M mediated EGFR TKI resistance through downregulation of AKT/catenin survivin signaling [74]. Hwa Young Lee et. al. showed that simvastatin treatment
was able restore expression of BIM and induce apoptotic cell death in H1975
cells harboring the T790M EGFR mutation [98]. In Hae Park et. al. suggested that the
combination of lovastatin and gefitinib can overcome resistance to gefitinib through down
regulation of RAS and inhibition of RAF/ERK and AKT [100]. Both, Mary E. Irwin et. al.
and Qiufang Chen et. al. has found that lovastatin induced cholesterol depletion from lipid
rafts was able to restore sensitivity to gefitinib in gefitinib resistant cell lines [70, 84]. While
the authors did not use a statin, Jiajin Li et. al. was able to show that inhibition of SREBP
increased gefitinib sensitivity through SREBP1 binding partner MARVELD1 by
decreasing cell membrane fluidity and as a result tyrosine phosphorylation of EGFR [101].
Taken together, these studies higlight the potential for a combination therapy targeting
cholesterol synthesis along with EGFR inhibition.
Since we have seen upregulation of CYP51A1 along with cholesterol synthesis in
our EGFR TKI DT model (Chapter 5), we hypothesize that a combination therapy of the
CYP51A1 inhibitor, ketoconazole, and an EGFR TKI will be able to downregulate
cholesterol synthesis and overcome the development of EGFR TKI tolerance. This work
is innovative because we will be the first to use a combination therapy of ketoconazole
and an EGFR TKI to target the development of EGFR TKI resistance.
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6.2

Results

Since we have seen upregulation of CYP51A1, leading to an increase in cellular
cholesterol levels, after treatment with EGFR TKIs in multiple lung cancer cell
lines, we set out to test the potential of a CYP51A1 inhibitor, ketoconazole, used in
combination with EGFR TKIs to overcome the development of EGFR TKI tolerance. We
first tested the sensitivity of parental and lapatinib DT cells to ketoconazole alone, using
monolayer IC50 analysis. Varying concentrations of ketoconazole (1.25-80M) were
added to the cells, in duplicates, the day after plating. Cell Titer Glo Assay (Promega)

Figure 27: Treatment of Lapatinib Tolerant Cells with the CYP51A1 Inhibitor,
Ketoconazole
A-E) Ketoconazole sensitivity in parental and lapatinib DT cell lines. H1650 (A),
H1299 (B), H1975 (C), and LLC (D) cells were treated the day after seeding, in
duplicates, with varying concentrations of the ketoconazole for 48 hours. Average
IC50 value is shown (E) (N=2). Statistical significance for each experiment was
determined using an un-paired T-Test comparing each parental cell line to the
corresponding DT cell line, * = p<0.05.
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was used 48 hours later to determine the relative cell number in each well. To calculate
IC50 for each cell line we used GraphPad Prism. Average luminescence value for each
group was plotted as a percentage of the control or untreated group. A non-linear
regression was then run to calculate the IC50 value. H1650, H1299, and LLC parental and
DT cells showed IC50s value ranging from 30-40M [Figures 27A (H1650), 27B (H1299),
and 27D (LLC)]. H1975 parental and DT cells had slightly higher IC50 values of about
50M (Figure 27C). None of the cell lines showed a statistically significant difference
between parental and DT cells (Figure 27E). We then tested a combination therapy of
lapatinib and ketoconazole. Addition of 20M ketoconazole to the culture media of H1650
parental cells, along with 6M lapatinib, reduced the viability of cells, however
ketoconazole alone, at this dose, was not very toxic to the cells (Figure 28).
Next, we asked what effect a constant does of ketoconazole would have on the
IC50 of lapatinib in both parental and EGFR TKI DT cells? The addition of 20M
ketoconazole, along with lapatinib or gefitinib, ranging from 1.25-80 M, was tested over
48 hours. We also tested H1650 cells grown on the FiSS, with 40M ketoconazole and
lapatinib, ranging from 2.5 – 160 M for 48 hours. In H1650 cells grown on monolayer
culture, the addition of ketoconazole was able to lower the IC50 of lapatinib by 2-fold in
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Figure 28: Addition of Ketoconazole to Parental Cells Stops the
Development of Lapatinib Tolerance
A) Parental- and DT- H1650 cells were plated and treated with 7.5M lapatinib,
20M ketoconazole, or a combination of both at the time of plating. They were
allowed to grow for 72 hours. Microscopy pictures were taken using bright field
microscopy at 100X.

parental cells and almost 3-fold in DT cells (Figure 29A). In H1650 cells grown on the
FiSS platform, the addition of ketoconazole was able to lower the IC50 of lapatinib by 2fold in parental cells and 5-fold in DT cells (Figure 29B). In H1299 cells, the addition of
ketoconazole lowered the IC50 of lapatinib by 3-fold in parental cells and over 10-fold in
lapatinib DT cells (Figure 29C). In H1299 cells, the addition of ketoconazole lowered the
IC50 of gefitinib over 6-fold in both parental cells and gefitinib DT cells (Figure 29D). In all
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Figure 29: Ketoconazole Lowers Cellular Sensitivity to Lapatinib
A-D) Lapatinib and ketoconazole combination sensitivity in parental and
lapatinib DT cell lines. Cells were treated the next day after plating with varying
concentrations of the identified drug/drugs for 48 hours. Monolayer and FiSS
drug sensitivity experiments were performed as described previously. Average
IC50 value ±SEM on monolayer and the FiSS is shown, H1650 N=4 (E) H1650
FiSS N=3 (F), H1299 lapatinib N=5 (G), and H1299 gefitinib N=5(H). CI was
calculated for each cell line using the average IC50 values. * = p<0.05, ** =
p<0.01, *** = P<0.001, **** = P<0.0001.

the lapatinib DT cell lines, the addition of ketoconazole significantly lowered the IC50 of
lapatinib in DT cells compared to parental [Figures 29E (H1650), 29F (H1650 FiSS), and
29G (H1299)]. Even in gefitinib in parental and gefitinib DT cells, this effect was found to
be statistically significant (Figure 29H).
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We next used the Combination Index (CI) calculation to determine the level of
synergism between EGFR TKIs and ketoconazole [70]. A CI<1 means the two drugs act
synergistically, a CI=1 means the two drugs have an additive effect, and a CI>1 means
the two drugs have an antagonistic effect. H1650 parental and DT cells, both on
monolayer and FiSS, showed a combination index was <1, which indicates that lapatinib
and ketoconazole inhibited cell growth synergistically (Figure 29). H1299 lapatinib and
gefitinib DT cells, along with parental, also showed synergistic response between the
EGFR TKIs and ketoconazole, with their Cis being <1 (Figure 29). It should be noted
however, that the combination index in H1650 DT cells, on monolayer and FiSS was lower
than in parental cells, indicating that the two drugs had an increased level of synergism
in the EGFR TKI DT cells. This same effect was seen in H1299 DT cells treated with
lapatinib and gefitinib.
We next investigated the effects of lapatinib and ketoconazole combination therapy
on cellular levels of cholesterol. Both H1650 and LLC parental and DT cells were treated
with 10M lapatinib plus or minus 20M ketoconazole for 48 hours before the cells were
collected. Cholesterol was extracted from cell pellets using a 30:20 solution of
Hexane/Isopropanol. Total cellular cholesterol was then determined using the Amplex
Red Cholesterol Assay Kit (Thermo Fisher Scientific). Average cholesterol content as a
percentage of control in drug treated cultures was then calculated. Cholesterol content
was normalized to untreated cells using cell count. Ketoconazole treatment alone did not
seem to have much of an effect on cellular cholesterol levels, as only in H1650 parental
cells treated with ketoconazole alone, did we find a significant decrease in cellular
cholesterol levels (Figure 30A). However, in both H1650 and LLC parental and DT cells
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we found that the addition of ketoconazole to lapatinib treatment was able to halt the
upregulation of cholesterol levels seen after treatment with lapatinib alone [Figures 30A
(H1650) and 30B (LLC)].

Figure 30: Ketoconazole can Halt the Upregulation of Cholesterol Synthesis
A-B) Cholesterol content after lapatinib and ketoconazole combination therapy.
Parental and lapatinib DT H1650 (A) and LLC (B) cells were treated the day after
seeding with 10µM lapatinib, 20µM ketoconazole, or a combination of both for 48
hours. Average fold change ±SEM, compared to untreated parental, is shown
(N=2). Statistical significance for each experiment was determined using an
ANOVA and the Tukey post hoc test, * = p<0.05, ** = p<0.005, *** = p<0.0005
compared to untreated.

Our next question was, can the EGFR TKI and ketoconazole combination therapy
induce apoptosis in EGFR TKI DT cells? Using flow cytometry, we measured the level an
annexin V and PI staining after treatment with lapatinib, ketoconazole, or a combination
of both. In both H1975 and H1299 the combination of 15M lapatinib and 20M
ketoconazole, was able to increase the levels of both annexin V positive and annexin V/PI
double positive cells over either drug by itself after 48 hours exposure. In the case of
H1975 cells, we found an increase of early plus late apoptotic cells from 34% to 51% in
parental to DT cells after treatment with the combination therapy, compared to 33% and
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20% respectively, with lapatinib alone (Figure 31A). In the case of H1299 cells, we found
early plus late apoptotic cells to be about 50% in parental to DT cells after exposure to
the combination therapy, compared to 30% and 20% respectively, with lapatinib alone
(Figure 31A). To further probe the cellular apoptosis pathway, we used traditional western
blotting. We found downregulation of survivin, and cleavage of both caspase-9 and PARP
in H1299, H1650, and H1975 cells after treatment with the combination therapy, whereas
lapatinib alone was unable to cause these effects (Figure 31B).

Figure 31: Lapatinib and Ketoconazole Combination Therapy Induces
Apoptosis
Parental and DT cells were treated the day after seeding with 15M lapatinib, 20M
ketoconazole, or a combination of both for 48 hours (N=2). (A) Annexin V/PI staining
of parental and lapatinib DT H1650 cells. (B) Apoptosis proteins in parental and
lapatinib DT cells. The expression of the indicated proteins was determined using
traditional western blotting. β-Actin was used as a loading control.
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Since we saw an increase in mitochondrial cholesterol levels in EGFR TKI cells,
we next evaluated the effect of the combination therapy on mitochondrial membrane
potential. To measure this, we used flow cytometry and JC-1 dye, which exhibits potentialdependent aggregation in the mitochondria and a red to green color shift caused by
changes in the concentration of red fluorescent JC-1 aggregates, as mitochondrial
depolarization is indicated by a decrease in red emitting aggregated JC-1 and an increase
in green emitting soluble JC-1 [102]. In H1299 parental and DT cells, after 48 hours of
combination therapy of 15M lapatinib and 20M ketoconazole we found a significant
decrease of almost 75% compared to untreated, in mitochondrial membrane potential in
both parental and lapatinib DT cells (Figure 32B). However, only in parental cells did
lapatinib alone caused a significant decrease of about 50% compared to control, in

Figure 32: Lapatinib and Ketoconazole Therapy Induces Apoptosis Through
Mitochondrial Depolarization
(A-B) Parental and DT cells were treated the day after seeding with 15M lapatinib, 20M
ketoconazole, or a combination of both for 48 hours (N=2). (A) Annexin V/PI staining of
parental and lapatinib DT H1975 cells. (B) JC-1 staining of parental and lapatinib DT
H1299 cells. Average PE/Alexa 488 ratio ±SEM is shown. * = p<0.05, ** = p<0.01, *** =
P<0.001, **** = P<0.0001.
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mitochondrial membrane potential (Figure 32B). Depolarization of the mitochondrial
membrane can lead to the release of cytochrome C from the mitochondria in the cytosol
in cells undergoing apoptosis [31].
Using the WES (Protein Simple) capillary immunoassay system we were able to
show that after treatment with 15M lapatinib and 20M ketoconazole combination
therapy for 48 hours, H1299 lapatinib DT cells had a significant increase in cytochrome
C levels in their cytosol compared to untreated, indicating release of cytochrome C into
the cytosol (Figures 33A and 33B). Taken together these results indicate that the
combination therapy of EGFR TKIs and ketoconazole is causing both parental and EGFR

Figure 33: Mitochondrial Depolarization Causes Cytochrome C Release After
Treatment with Lapatinib and Ketoconazole
(A-B) Cytochrome C release in lapatinib DT H1299 cells after exposure to
lapatinib, ketoconazole or combination. (A) WES automated capillary western
blotting of whole cell lysate using antibodies against the indicated proteins. (B)
Analysis of cytosolic cytochrome C was determined using area AUC
measurements generated using Compass software for Simple Western (Protein
Simple). Vinculin was used as a loading control to normalize AUC measurements.
Average normalized fold change ±SEM, compared to untreated, is shown. * =
p<0.05, ** = p<0.01, *** = P<0.001, **** = P<0.0001.
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TKI DT cells to undergo apoptosis through mitochondrial depolarization, the release of
cytochrome C, and the subsequent cleavage of caspase-9 and PARP.
We then set out to develop a mouse model of acquired EGFR TKI DT to test our
novel combination therapy. Using two different mouse models, H1650 xenograft and
immunocompetent LLC1 allograft, we were able to replicate the in vitro model of EGFR
TKI DT Nu/Nu nude mice (N=3/group) were injected subcutaneously on the flank with 3
million H1650 cells. Mice began treatment when tumors became palpable (3mm
diameter). C57BL/6 mice (N=2 Control) (N=4 LP) were injected subcutaneously on the
flank with 1 million LLC cells. Mice were treated every day with vehicle control or 50mg/kg
lapatinib (day 26 for H1650 tumors and day 9 for LLC tumors). Drugs were dissolved in
0.1% Tween 20 with 5%DMSO in water and injected intraperitoneally. H1650 mice were
treated for 12 days and LLC mice were treated for 6 days. Tumor size was monitored
using caliper measurement. Tumors were collected when controls reached 10mm X
10mm. In both cell lines, lapatinib was able to decrease tumor size at least 3-fold
compared to untreated, however the lapatinib treated tumors steadily grew after treatment
was withdrawn [Figures 34A (H1650) and 34B (LLC)].
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We next collected the tumors and examined both total cellular cholesterol as well
as protein levels of cholesterol synthesis enzymes. Using the WES (Protein Simple)
capillary immunoassay system we examined the levels of the cholesterol synthesis
enzymes CYP51A1, LSS, and DHCR24 in both LLC parental and DT cells grown on the
FiSS, as well as control and lapatinib treated LLC mouse tumors to determine if cells
grown on the FiSS platform were behaving similar to cells in vivo with respect to
cholesterol synthesis (Figure 35A). Using AUC analysis, we found a 5-fold increase in
CYP51A1 protein levels in FiSS DT cells compared to FiSS parental cells and a 7-fold
increase in the lapatinib treated tumors compared to control tumors (Figure 35B). For
DHCR24 we observed a 3-fold increase in FiSS DT cells compared to FiSS parental cells

Figure 34: In Vivo Mouse Model of EGFR TKI Resistance
Mice were injected subcutaneously on flank with 3 million H1650 cells (A)
(N=3/group) (Nu/Nu nude mice) or 1 million LLC cells (B) (N=2 Control) (N=4 LP)
(C57BL/6). Tumors were allowed to grow until they reached 3mm X 3mm. Mice
were then treated every day with vehicle control or 50mg/kg lapatinib for 12 days
(H1650) or 6 days (LLC). Tumor volume ±SEM over time is shown. * = p<0.05, ** =
p<0.01, *** = P<0.001, **** = P<0.0001.
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and about a 6-fold increase in lapatinib treated tumors compared to control tumors [Figure
35C). For LSS we discovered a 7-fold increase in FiSS DT cells compared to FiSS
parental cells and a 7-fold increase in lapatinib treated tumors compared to control tumors

Figure 35: Upregulation of Cholesterol Metabolism in the In Vivo Mouse Model
of EGFR TKI Resistance
(A-E) Cholesterol synthesis enzyme protein expression in vehicle and lapatinib
treated LLC1 tumors. (A) WES automated capillary western blotting of whole tumor
cell lysate using antibodies against the indicated proteins. The expression of
CYP51A1 (N=6) (B), LSS (N=6) (C), and SREBP2 (N=3) (D) was determined using
AUC measurements generated using Compass software for Simple Western (Protein
Simple). β-actin was used as a loading control to normalize AUC measurements.
Average normalized fold change ±SEM, compared to vehicle treated tumors, is
shown. (E) Cholesterol content of vehicle and lapatinib treated LLC1 tumors.
Average fold change ±SEM, compared to vehicle treated tumors, is shown (N=7).
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(Figure 35D). Cholesterol was extracted tumors using a 30:20 solution of
Hexane/Isopropanol. Total cellular cholesterol was then determined using the Amplex
Red Cholesterol Assay Kit (Thermo Fisher Scientific). Average cholesterol content as a
percentage of control in drug treated tumors was then calculated. Cholesterol content
was normalized to control using cell tissue weight. In the tumors we also found cholesterol
levels within the lapatinib treated tumors to be 1.5-fold higher than untreated tumors
(Figure 35E).
Lastly, we used in vivo tumor model to determine the effectiveness of our novel
combination therapy. C57BL/6 mice (N=5/group) were injected subcutaneously on the
flank with 1 million LLC cells. Mice began treatment when tumors became palpable (3mm
diameter), which was day 6 in this case. Mice were then treated every day with either
vehicle control, 50 mg/kg lapatinib, 20 mg/kg ketoconazole, or the combination of lapatinib
and ketoconazole. Drugs were dissolved in 0.1% Tween 20 with 5%DMSO in water and
injected intraperitoneally. Tumor size was monitored using caliper measurement. We
found that the both the combination therapy and lapatinib alone were able to significantly
decrease tumor size by over 2-fold compared to control (Figure 36A). Tumors were
collected when controls reached 10mm X 10mm and flow cytometry was used to examine
annexin V/PI staining, as well as JC-1 staining. The results showed the combination
therapy treated tumors, unlike lapatinib or ketoconazole alone, had decreased
mitochondrial membrane potential, about 50% of untreated tumors (Figure 36B). We also
observed an increase in late apoptotic cells in the tumors treated with the combination
therapy (43%) compared to lapatinib (16%) and ketoconazole (18%) alone (Figure 36C).
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Figure 36: In Vivo Validation of Lapatinib Plus Ketoconazole Therapy
A) C57BL/6 (N=5/group) were injected subcutaneously on flank with 1 million LLC cells.
Tumors were allowed to grow until they reached 3mm X 3mm. Mice were treated every
day with vehicle control, 50mg/kg lapatinib, 20mg/kg ketoconazole, or a combination of
both until collection. Statistical significance for each experiment was determined using a
paired T-Test, * = p<0.05 compared to untreated. (B) The tumors (N=2/group) were then
harvested when they reached 10mm X 10mm and digested using MACS Miltenyi Biotec
Mouse Tumor Dissociation kit and gentle MACS Dissociator according to the
manufactures’ protocol. They were then stained with JC-1 (Thermo Fisher Scientific)
according to the manufactures' protocol and assayed by flow cytometry. Statistical
significance for each experiment was determined using an ANOVA and the Tukey post
hoc test, * = p<0.05 compared to untreated. (C) Cells were collected as stated above
and then stained for Annexin V and PI using the BD Pharmingen FITC Annexin V
Apoptosis Detection Kit I according to the manufactures' protocol and assayed by flow
cytometry.
Nu/Nu nude mice (N=5/group) were injected subcutaneously on the flank with 3
million H1650 cells. Mice began treatment when tumors became palpable (3mm
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diameter), which was day 10 in this
case. Mice were then treated every
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Figure 37: In Vivo Validation of Lapatinib Plus
Ketoconazole Therapy
A) Nu/Nu nude (N=5/group) were injected
subcutaneously on flank with 3 million H1650
cells. Tumors were allowed to grow until they
reached 3mm X 3mm. Mice were treated every
day with vehicle control, 50mg/kg lapatinib,
20mg/kg ketoconazole, or a combination of both
until collection. Statistical significance for each
experiment was determined using a paired TTest, * = p<0.05, ** = p<0.005, *** = p<0.0005.

injected

intraperitoneally.

Tumor size was monitored using
caliper measurement. We found
that only the combination was
able to significantly decrease
tumor

size

by

over

3-fold

compared to control at day 31
(Figure 37). At day 36 lapatinib
alone was able to reduce tumor
size by about 2-fold (Figure 37).

On this same day the combination therapy was able to shrink tumor growth by over 2-fold
compared to both ketoconazole alone and the control treated tumors. This data highlights
the ability of ketoconazole and EGFR TKI combination therapy to overcome the
development of EGFR TKI resistance both in vitro and in vivo.
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6.3

Discussion

It is important to note that our models of EGFR TKI tolerance are different than many of
the cell line models that most EGFR TKI combination therapies mentioned above are
tested in. Many of those combination therapies are tested in EGFR TKI naïve cells,
meaning they have not been previously exposed to EGFR TKIs. The EGFR TKI resistant
cell lines that many of these manuscripts refer to are H1975 cells that harbor the T790M
mutation in EGFR, whereas our EGFR TKI DT models have been exposed to EGFR TKIs
before the experiments were run. Using our models of EGFR TKI DT, we tested a novel
combination therapy of ketoconazole and EGFR TKIs to determine if it could be used to
overcome the development of EGFR TKI resistance.
Ketoconazole, a potent inhibitor of CYP51A1 along with CYP3A4, is an FDA
approved broad-spectrum systemic antifungal agent and also used in the treatment of the
hormone-dependent prostate cancer, due to its ability to block steroidogenesis [103-105].
Ketoconazole has also been studied to examine its cytotoxic effects when used as a
single agent, and synergistic when combined with chemotherapeutics [103, 105, 106].
Mikhail V. Blagosklonny et. al. found that the addition of ketoconazole potentiates the
antitumor effects of microtubule- active drugs such as paclitaxel and vinblastine on
prostate cancer cells [107]. William D. Figg et. al. ran a phase 1 clinical study of
ketoconazole and docetaxel for metastatic castration resistant prostate cancer, finding
that the combination therapy led to significantly longer overall survival in docetaxel naïve
patients [103]. When it comes to ketoconazole and EGFR TKIs, the available data is
limited. In one study, Deborah A. Smith et. al. examined the impact of ketoconazole
induced CYP3A4 inhibition on lapatinib pharmacokinetics [106]. The authors found that
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systemic exposure to lapatinib was significantly increased by inhibition of CYP3A4, most
likely due to the fact that CYP3A4 is the primary metabolizing enzyme for lapatinib [106].
Since CYP3A4 is the most abundant cytochrome P-450 expressed in human liver and it
contributes to the metabolism of many drugs in use today, this may serve to at least
partially explain the combination effects seen by some drugs with ketoconazole, a potent
CYP3A4 inhibitor [108]. To our knowledge ketoconazole is not currently being used as a
treatment for any types of lung cancer.
After treatment with the EGFR TKI plus ketoconazole combination therapy we
found a stoppage of the EGFR TKI induced cholesterol upregulation and an activation
of apoptosis. Without the buildup of cholesterol in the mitochondrial membrane the cells
were not able to resist MOMP. Thus, apoptosis was activated by mitochondrial
membrane depolarization caused by MOMP, leading to cytochrome C release into the
cytosol and subsequent cleavage of caspase-9 and PARP, leading to cell death in both
parental and EGFR TKI DT cells.
We were able to recapitulate some of the main monolayer in vitro results both on
the FiSS platform and in an in vivo mouse model of EGFR TKI DT. On the FiSS LLC DT
cells showed an upregulation of cholesterol syntheisis enzymes that was mirrored in
LLC mouse tumors after treatment with lapatinib. The synergistic nature of the lapatinib
and ketoconazole interaction in the cells was also recaptured using the FiSS platform
with H1650 cells. Treatment with the combination therapy was able to significantly stunt
tumor growth. Though, lapatinib proved to be almost as efective. However, the
combination therapy did increase mitochodrial membrane depolarization of cells within
the tumor, as well as the percentage of apoptotic cells within the tumor, compared to
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either drug alone. It is possible that if the studies were continued longer we would see
an increased difference between tumor size of lapatinib alone and the combination
therapy. Taken together these results suggest that further research is warranted to
determine if treatment of EGFR TKIs along with ketoconazole could be used to stop
the development of EGFR TKI resistance in the clinic.
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CHAPTER 7:
A META-ANALYSIS OF DIFFERENTIAL GENE EXPRESSION IN EGFR TKI
RESISTANT CELL LINES REVEALS NOVEL THERAPUTIC TARGETS

7.1

Introduction

With the intent to investigate the development of drug resistance to EGFR TKIs, ten
publicly available RNA-Sequencing datasets were downloaded from the National Center
for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database [38].
All of these datasets contain data comparing cell lines treated with EGFR TKIs and their
corresponding untreated or parental cells (Table 8) [47, 48, 50-52]. The fasta files for each
dataset were downloaded from the GEO database and analyzed for differential gene
expression using tools available on Galaxy, an open-source, free of charge, web-based
platform [39]. By uploading data to the Galaxy software framework, users can perform
computational analyses, though the website, on large biomedical datasets, including
those generated in genomics, proteomics, metabolomics and imaging. Galaxy works by
Table 8: EGFR TKI Resistant Datasets
Data

Data

Data

Data

Set 1

Set 2

Set 3

Set 4

47

44

49

49

Data Set
5

48

Data

Data

Data

Data

Data

Set 6

Set 7

Set 8

Set 9

Set 10

45

45

45

45

45

Accession

GSE80802

GSE62118

GSE79688

GSE79688

GSE117610

GSE75602

GSE75602

GSE75602

GSE75602

GSE75602

CELL LINE

HCC4006

HCC827

HCC827

HCC4006

PC9

PC9

PC9

PC9

PC9

PC9

EGFR TKI

Gefitinib

Erlotinib

Gefitinib

Gefitinib

Gefitinib

Gefitinib

Gefitinib

Gefitinib

Gefitinib

Gefitinib

MAX [C]

100nM

2uM

Up to 3uM

Up to 3uM

50nM

1mM

Not
Specified

Not
Specified

Not
Specified

Not
Specified

LENGTH
OF TX

24 Hours

47 Days

Not
Specified

Not
Specified

6 Days

24 Hours

Not
Specified

Not
Specified

2 Weeks

2 Weeks

Raw RNA-SEQ datasets (.fasta files) were downloaded using the National Center for Biotechnology Information (NCBI) Gene
Expression Omnibus (GEO) database. Data was originally obtained by authors of the referenced manuscripts. Each dataset
contains .fasta files for control cells and EGFR TKI resistant cells. This table details available information about the EGFR TKI
used to make the resistant cell line, length of EGFR TKI treatment used to confer resistance, and the max EGFR TKI
concentration that resistant cells were exposed to in their growth media.
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interacting with the servers that run the analysis tools and the disks that store the raw
data, while the user only needs to interact with the website. The main public Galaxy server
(https://usegalaxy.org), online since 2007, features a robust toolset for large-scale omics
analyses, a large amount of public data for use, and analysis histories and workflows.
A schematic of the workflow for RNA-SEQ data analyses is shown in Figure 38.
Briefly, after uploading the data to Galaxy, the raw sequencing data was quality checked
using FASTQC [40]. FastQC performs quality control checks on raw sequence data by
using a modular set of analyses to give the researcher a short impression of whether the
data has any problems that could affect downstream analysis. Then low-quality
transcripts, adaptor sequences, and PCR primers sequences were removed using
Trimmomatic [41]. Trimmomatic performs a selection of trimming steps designed
specifically for illumina paired-end and single ended data. The cleaned sequences were
then aligned to the human genome using HISAT2 [42]. HISAT is a spliced alignment
program that allows for fast and sensitive alignment of reads to a reference genome.
Count tables measuring gene expression were then created using featureCounts [43].
FeatureCounts is a read counting program that can be used to count both gDNA-seq and
RNA-seq reads for genomic features. Differential gene expression was then calculated
from the count tables using DESeq2 [44]. Using a negative binomial distribution model,
DESeq2 takes count data, estimates variance-mean dependence, and calculates
differential expression. Gene fold changes represent drug resistant against parental,
meaning the values correspond to up or down regulations of genes in drug resistant
samples, and were considered significantly differentially expressed if the corrected pvalue was <.05.
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Figure 38: Workflow for RNA-SEQ data analysis
Datasets were analyzed for differential gene expression using the indicated tools,
which are available on Galaxy, an open-source web-based platform. The raw
sequencing data was processed to remove any adaptor, PCR primers and lowquality transcripts using FASTQC and Trimmomatic. The samples were then aligned
against human genome using HISAT2. Gene expression measurement was then
performed from aligned reads using featureCounts. Differential gene expression was
calculated using DESeq2.

IPA was then used to identify pathways that could affected by the significantly
differential expressed genes [36]. IPA uses a database of prior biological knowledge to
interpret gene-expression data and create predictions of the status of regulatory
molecules that could explain the observed expression changes in datasets. A suite of
algorithms and tools for inferring and scoring data within the analytics tools that enable
researchers to combine directional information with knowledge from the literature to infer
causes and predict likely outcomes from datasets. The knowledge base of this software
consists of algorithms that identify functions, pathways, regulators, relationships, and
mechanisms relevant to changes observed in a dataset. These are derived from exploring
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and annotating the peer reviewed scientific literature. Available tools include, Upstream
Regulator Analysis, Mechanistic Networks, Causal Network Analysis, and Downstream
Effects Analysis. To begin our analysis, we ran a comparison analysis in IPA to compare
the parental vs drug tolerant data obtained from each dataset. To determine the most
significantly affected pathways, we sorted them according to their average Z scores. Z
score are statistical measures of the match between expected relationship direction and
observed gene expression, between datasets. We then examined the datasets for
similarly affected canonical pathways and likely upstream regulators responsible for the
observed gene expression changes.

7.2

Results

The EGFR TKI resistant cell lines in each dataset were obtained via different protocols,
as each protocol was developed and verified by the researchers that obtained the original
RNASeq data. IPA comparison analysis of canonical pathways predicted to be most
affected by the differently expressed genes in each dataset showed very little consensus
between all of the datasets (Figure 39A/B). This is most likely because all of these EGFR
TKI resistant models were produced using different methods, treatment times, and EGFR
TKIs, along with different lung cancer cell lines (Table 8). However, most of the datasets
agreed in a few pathways. One such pathway was oxidative phosphorylation. A strong
decrease in oxidative phosphorylation was seen in 7 of 10 of the EGFR TKI resistant cell
lines (Figure 39A). IPA also identified cholesterol synthesis as strongly downregulated in
7 of the 10 datasets (Figure 39A). Downstream EGFR signaling molecules such as
PI3K/AKT and phospholipases were predicted to be upregulated in a majority of the
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datasets (Figure 39A). Molecules such as MAPK1 (Mitogen-activated protein kinase 1),
HER2, MEK, STAT1 (Signal transducer and activator of transcription 1), and MYC (MYC
Proto-Oncogene ) show up as possible upstream regulators of the genetic changes seen
in the differential gene expression datasets, but again there is very little agreement
(Figure 39B). The variability in genetic changes leading to EGFR TKI resistance seen
here serves to highlight the many different pathways and genetic endpoints that can
cause lung cancer cells to become resistant to EGFR TKIs.

Figure 39: Comparison Analysis
IPA was used to identify the pathways that are affected by differentially expressed
genes in each dataset. A comparison analysis was run to compare the obtained
differential gene expression data from each dataset. Affected canonical pathways (A)
and likely upstream regulators (B) responsible for the observed gene expression

To move forward we decided to take a closer look at the oxidative phosphorylation
pathway, as well as phospholipase signaling. To our knowledge, these two pathways are
not very well studied in the context of resistance to EGFR TKI therapy. Genes comprising
the oxidative phosphorylation pathway, as a whole, were strongly downregulated in 7 of
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the 10 datasets (Figure 40A). Further analyses indicated that in the different EGFR TKI
resistant cell lines different genes of this pathway contributed to the downregulation. Out
of the 82 genes listed in the IPA database under canonical oxidative phosphorylation in

Figure 40: Oxidative Phosphorylation
A) Expression levels of select genes involved in oxidative phosphorylation from each
RNASeq dataset according to IPA. Fold change values were calculated against the
control cells for each dataset. B) IPA generated network map showing known
connections between genes involved in oxidative phosphorylation and those found in
the RNASeq datasets with EGFR.

our comparison analysis, only 10 showed up as significantly differently expressed in 4 or
more of the datasets (Figure 40A). We next took all 82 of the oxidative phosphorylation
genes in IPA and used the software to plot all known interactions between these genes
and EGFR. Eleven of these genes have known interactions with EGFR and of these,
ATP5F1A (ATP Synthase F1 Subunit Alpha) was significantly downregulated in 6 of the
10 EGFR TKI resistant cell lines and to our knowledge has no previously known role in
EGFR TKI resistance (Figure 40B).
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Figure 41: Phospholipase Signaling
A) Expression levels of key phospholipases from each RNASeq dataset according to
IPA. Fold change values were calculated against the control cells for each dataset.
B) IPA generated network map showing known connections between
phospholipases found in the RNASeq datasets with EGFR.

Further analyses indicated that in the different EGFR TKI resistant cell lines
different genes with phospholipase activity contributed to this upregulation (Figure 41A).
We next took all 47 phospholipase genes in the IPA database and used the software to
plot all known interactions between these genes and EGFR. Nine of these genes have
known interactions with EGFR, but to our knowledge have no known role in resistance to
EGFR TKI therapy (Figure 41B). Genes involved in both oxidative phosphorylation and
phospholipase signaling may serve as novel targets to overcome resistance to EGFR
TKII treatment.
We then used an in vivo xenograft tumor model of EGFR TKI resistance to
determine if we could replicate any of the RNASeq results. In H1650 tumors we found
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that lapatinib alone was able to significantly decrease tumor size by about 2-fold
compared to control at day 49 (Figure 42A). However, the lapatinib treated tumor was
growing at a steadily increasing rate, indicating a building resistance to the therapy. To
further investigate the cellular mechanisms responsible for EGFR TKI resistance we

Figure 42: Protein Array Analysis of a In Vivo Xenograft Tumor Model of EGFR
TKI Resistance
A) Mice were inoculated with H1650 human lung cancer cells. Mice began treatment
when tumors became palpable (2-3mm diameter) and were treated every day with
vehicle control or 50mg/kg lapatinib (N=3), * = p<0.05. B) Relative protein
abundance of lapatinib vs control tumors. Protein was collected from H1650 tumors
(N=3), samples were pooled equally, and the PhosphoExplorer antibody array was
performed (Full Moon Biosystems). RFU for all significantly differently expressed
proteins is shown (N=2). * = p<0.05, ** = p<0.01, *** = P<0.001.

performed the Phospho-Explorer Antibody Array (Full Moon Biosystems) on the control
vs lapatinib treated tumor samples. This array is used for broad-scope protein
phosphorylation profiling and consists of 1318 antibodies related to multiple signaling
pathways and biological processes. When comparing protein expression in control vs
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lapatinib treated tumors we found a significant downregulation of some known resistance
markers such as, VEGFR2 (Vascular endothelial growth factor receptor 2), Abl1 (ABL
Proto-Oncogene 1), Src (Proto-oncogene tyrosine-protein kinase Src), Myc, and
upregulation of the NF-kB inhibitior IkB-alpha (Figure 42B). This may be due to the
lapatinib treated tumors still being in the early stages of resistance development, as the
tumors were still growing at a slower rate than the control (Figure 42A). We did find
upregulation of MEK1, a signaling protein downstream of multiple growth factor receptors
including EGFR. MEK1 is a well-known marker of resistance to EGFR TKIs (Figure 42B).
To the best of our knowledge, the rest of the significantly differential expressed proteins
we found using this array have little or no known connection to EGFR TKI resistance
(Figure 42B).
To further explore EGFR TKI resistance by combining our datasets with the
publicly available data, we produced a list containing significantly changed genes that are
commonly up or down regulated in 6 or more of the RNASeq datasets and added the
significantly changed proteins from the PhosphoExplorer array. We then plotted all known
interactions between the list and EGFR (Figure 43A). Known pathways in IPA for cellular
signaling/ metabolic processes were then overlaid on this plot and we kept only genes or
proteins that directly interacted with our pathways of interest (Figure 43B). Using this data
we can observe how these proteins interact and connect to known mechanisms of EGR
TKI resistance, such as STAT3, ERK/MAPK, and NF-kB signaling. We also show how
these commonly differentially expressed genes/proteins interact with our candidate
pathways (oxidative metabolic processes and phospholipases) while also tracing them
back to the EGFR signaling pathway (Figure 43B). Finally, we produced a gene map
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Figure 43: IPA Network Map of RNASeq and Protein Array Data
A) IPA generated network map showing known connections between the most
common genes found in the RNASeq datasets and those found in the protein array
with each other and EGFR. B) IPA generated network map showing known
connections between the most common genes found in the RNASeq datasets and
those found in the protein array with EGFR and known pathways in IPA for cellular
signaling/ metabolic processes of interest.

showing genes that were commonly up or down regulated in six or more datasets but
have no known interactions with the EGFR pathway in the IPA database (Figure 44).
Using data obtained from the 10 EGFR TKI resistant cell lines and the protein array data
from EGFR TKI treated xenograft tumors, we have produced a number of novel targets
that may prove useful when designing new therapies to overcome EGFR TKI resistance
in lung cancer.
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Figure 44: Differentially Expressed Genes Without Experimentally Validated
Connections to the EGFR Pathway in the IPA Database
IPA generated gene map showing genes that were commonly up or down regulated
in six or more datasets but have no known experimentally validated connections to
the EGFR pathway in the IPA database.

Discussion:
In this study, we aimed to use the RNASeq data from ten different EGFR TKI resistant
models to attempt to find novel pathways leading to EGFR TKI resistance. After
generating differential gene expression lists for each dataset and comparing them using
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IPA, we could not find a single gene that was up or downregulated in every dataset. In
fact, we were not able to identify even one specific biological pathway that was predicted
to be up or downregulated in every dataset. One of the main reasons that EGFR TKI
resistance has proven so difficult to overcome is the molecular and genetic variability that
can lead to EGFR TKI resistance [109]. The next approach we took was to look at
pathways that were determined by IPA to be significantly affected and showed agreement
between a majority of the datasets.
A major finding of our analyses is that one pathway (oxidative phosphorylation)
was downregulated in 7 of the 10 EGFR TKI resistant cell lines. Therefore, it may be
possible to target EGFR TKI resistance through this strong decrease in oxidative
phosphorylation. This finding is consistent with several other reports. For example, ChunTe Chiang et. al. found that oxidative phosphorylation was downregulated in a group of
NSCLC patients with mutated EGFR tumors that also had high mTORC2 (Mammalian
target of rapamycin complex 2) activity, leading to a worse prognosis [110]. Viviana De
Rosa et. al. found that inhibition of EGFR signaling induced an upregulation of oxidative
phosphorylation in NSCLC cell lines [111]. Mingtong Ye et. al. found that erlotinib resistant
lung cancer cells have mitochondrial dysfunction and rely more on glycolysis for survival
non-resistant cells and that glucose deprivation can selectively decrease their viability
[112]. Imoh S. Okon et. al. found that in lung cancer cells chronic gefitinib treatment
promotes ROS (Reactive oxygen species), which then activates an EMT and and
mitochondrial dysfunction, leading to gefitinib resistance [113]. However, not all of the
literature is in agreement. Matthew J. Martin et. al. showed that inhibition of oxidative
phosphorylation in combination with osimertinib could delay or prevent the development
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of resistance to osimertinib, as osimertinib treatment was shown to induce a strict
dependence on mitochondrial oxidative phosphorylation in EGFR mutant lung cancer cell
lines [114]. Yuting Sun et. al. showed a glycolysis-to-OxPhos shift in eroltinib resistant
EGFR mutant lung cancer cells that have undergone EMT (Epithelial–mesenchymal
transition) [115]. While oxidative phosphorylation’s role in EGFR TKI resistance is pivotal,
the reason for the discrepancy among the reports is unclear. This may be attributed to
differences in mutation status and cellular context within the many different cell line
models have been developed to study EGFR TKI resistance in lung cancer. These include
chronic adaptation model, tolerance model, and loss of function model [47-52]. Our study
has identified reactivation of oxidative phosphorylation, possibly by upregulation of
ATP5F1A, as a potential therapeutic strategy to overcome EGFR TKI resistance.
Another major finding of our study is that we identified an increase in
phospholipase expression and signaling as a potential therapeutic target. While the role
phospholipases play in EGFR activation and downstream signaling has been well studied,
their contribution to EGFR TKI resistance has not been defined [116-120]. In our study,
we have found phospholipase gene expression to be upregulated in 7 of the 10 EGFR
TKI resistant cell lines. It is possible that due to the essential roles phospholipases play
in maintaining EGFR signaling that the upregulation seen in these EGFR TKI resistance
cell lines serves to overcome EGFR inhibition by TKIs. More work needs to be done to
determine the exact role that phospholipases are performing to contribute to TKI
resistance.
To further explore EGFR TKI resistance, we used an in vivo xenograft tumor model
of EGFR TKI resistance and performed the PhosphoExplorer array on the tumor samples.
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Using this data and the RNASeq data we connected known mechanisms of EGR TKI
resistance, such as STAT3, ERK/MAPK, and NF-kB signaling to oxidative metabolic
processes and phospholipases. This highlights the interplay between different
mechanisms of EGFR TKI resistance, both known and predicted, and shows that in most
cases resistance is not just conferred by one pathway or gene but in fact multiple
pathways work synergistically to enhance cellular resistance to EGFR TKIs. Lastly, we
produced a gene map showing genes that were commonly up or down regulated in a
majority of the datasets but have no experimentally validated known interactions with the
EGFR pathway in the IPA database. Literature searches of the upregulated genes
identified a few that may play a role in EGFR TKI resistance. In one study, SEMA3C
(Semaphorin 3C) was found to drive activation of multiple RTKs, including EGFR, and
SEMA3C expression levels increased in castration-resistant prostate cancer, where it
functioned to promote cancer cell growth and resistance to androgen receptor pathway
inhibition [121]. A tandem duplication at 7q34 leading to a fusion between KIAA1549 and
BRAF was found in 66% of pilocytic astrocytomas, and lead to constitutive BRAF kinase
activity and was able to transform NIH3T3 cells [122]. In another study, a systems
analysis of a model of EGFR-mutated NSCLC resistant to targeted therapy was
performed using whole exome sequencing, global time-course discovery phosphoproteomics and computational modeling to identify resistance pathways and one of the
nine phosphoproteins whose corresponding genes were directly mutated was found to be
AHNAK2 (AHNAK Nucleoprotein 2) [123]. Further experimentation is needed to confirm
the possible roles these genes play in the development of EGFR TKI resistance.
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In one interesting note, dataset number 6 was not an EGFR TKI resistant cell line
but parental cells treated with an EGFR TKI for 24 hours before collection for RNA
sequencing. This dataset showed to be strongly opposite in a number of pathways that
the other datasets showed some agreement. This was seen in EGFR downstream
signaling, as it was strongly downregulated in this sample as opposed to up regulated in
the majority of the others. The best example of this is in cholesterol synthesis, as it was
strongly upregulated in this sample, but downregulated or unchanged in all of the other
datasets. In previous chapters we have also shown a strong upregulation of cholesterol
synthesis in parental cells treated with EGFR TKIs that is maintained in the presence of
EGFR TKIs, at least out to 60 days. The reason that these other EGFR TKI resistant cell
lines are showing a down regulation in cholesterol synthesis may be due to the fact that
they were all selected from cell populations that had acquire resistance mechanisms to
EGFR TKIs that allowed for a complete bypass of EGFR. That is why we see upregulation
of EGFR downstream signaling in most of these cell lines. They no longer need EGFR
for pro-survival and pro-growth signaling, as they get it elsewhere. Whereas the parental
treated cells do not have a resistance mechanism to bypass their need for EGFR signaling
and thus upregulate anti-apoptotic signaling in an attempt to survive until they acquire a
resistant mechanism. This is just a theory and would have to be tested but may serve to
explain this phenomenon. Dataset 1 was also 24 hour EGFR TKI treated parental cells,
however unlike dataset 6 the cells were treated with only 100nM EGFR TKI compared to
1mM. This lower concentarion of EGFR TKI may not have been enough to stimulate a
survival response, which is why we do not see cholesterol synthesis upregulated in this
dataset. There is some evidence for this as, Aaron N Hata et. al. found that that EGFR
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TKI resistant cancer cells can both pre-exist and evolve from drug-tolerant cells that show
diminished apoptotic response to EGFR TKIs [48]. The authors also found that the path
taken to resistance will impact the final biology of the resistant clone. It may be that
pathways which confer survival ability to the initial insult with an EGFR TKI are no longer
needed once the cell acquires resistance to the EGFR TKI, so the cell compensates for
this by turning the pathway in the opposite direction. In this case, depending on the stage
of resistance the cell may be using molecular pathways that it will not need once it reaches
the next stage and this may serve to explain the variability we see when analyzing
resistant mechanisms in a wide variety of EGFR TKI resistant cell lines.
Through a set of bioinformatics analyses using available RNA-Sequencing and
protein array datasets comparing lung cancer cell lines treated with EGFR TKIs until
resistance and their corresponding parental cells analyzed for differential gene
expression, we have identified several novel EGFR TKI resistance targets.
Downregulation of oxidative phosphorylation and upregulation of phospholipase signaling
seen in the majority of EGFR TKI resistant models serve as promising therapeutic targets
for overcoming EGFR TKI resistance. Overlap between known mechanisms of resistance
and these pathways highlights the fact that EGFR TKI resistance most likely is the result
of multiple pathways working synergistically. By studying the cellular effects of acquired
EGFR TKI resistance, as well as the mechanism through which this resistance is
maintained, we can better understand how lung cancer cells become drug resistant to
EGFR TKIs and help design more efficient combination treatment strategies that will stop
the development of resistance.
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CHAPTER 8:
CONCLUSION

In conclusion, we have created and validated a model for EGFR TKI resistance and
successfully used this model to examine the mechanisms of cell survival following EGFR
TKI exposure and elucidate a method of overcoming this survival to eliminate
development of EGFR TKI resistance. To our knowledge, we are the first lab to show the
upregulation of cellular and mitochondrial cholesterol synthesis after exposure to EGFR
TKIs, both in vitro and in vivo. Thus, producing the anti-apoptotic effect of stopping the
release of cytochrome C into the cytosol. We are also the first to demonstrate the
effectiveness of a ketoconazole plus EGFR TKI combination therapy in overcoming the
development of resistance to EGFR TKIs, both in vitro and in vivo.
In chapter 4 will detailed the development of EGFR TKI drug tolerant (DT) human
lung cancer cell lines as model for de novo drug resistance. We also used mass
spectroscopy to find over 500 different proteins that are significantly differentially
expressed in DT cells compared to parental cultures. Specifically, the protein CYP51A1
was significantly up-regulated in the DT cells compared to the parental cells.
Chapter 5 explained the anti-apoptotic role of cholesterol in helping the cells to
survive the initial exposure to EGFR TKIs. Differences in total cellular cholesterol and
more specifically, mitochondrial cholesterol, were upregulated in DT cells, as well as
parental cells treated with EGFR TKIs for as little as 48 hours. This upregulation of
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cholesterol synthesis provides a potential target to block the development of EGFR TKI
tolerance in these cells.
Chapter 6 introduced a novel combination therapy of the CYP51A1 inhibitor,
ketoconazole, and EGFR TKIs to block the development of EGFR TKI resistance.
Ketoconazole and EGFR TKIs acted synergistically to induce apoptosis and overcome
the development of EGFR tolerance by halting the upregulation of cholesterol and thus
allowing for the release of cytochrome C from the mitochondria. This combination
therapy was also able to shrink the growth of flank tumors in an in vivo mouse model of
EGFR TKI resistance.
Chapter 7 described a meta-analysis of publicly available RNA sequencing datasets
dealing with EGFR TKI resistance in lung cancer with a focus on finding common
pathways to the development of EGFR TKI resistance across a number of different
model systems. By using our models of acquired EGFR TKI resistance we were able to
study the acquisition of resistance to EGFR TKIs in lung cancer cells and develop a
combination therapy with the potential to overcome EGFR TKI resistance. The one
question that remains unanswered after these studies is, how the inhibition of EGFR by
EGFR TKIs is inducing the upregulation of cholesterol that we see in our model?
In our model we found the upregulation of SREBP2, which is a transcription factor
that controls, among other things, the transcription of cholesterol synthesis genes [124].
So, this could explain why we see upregulation of cholesterol, but the question of how
EGFR inhibition by EGFR TKIs is activating SREBP2 still remains? Contrary to this, it is
well know that active EGFR signaling promotes the activation of SREBP2 through
AKT/mTOR signaling [125]. So in the absence of EGFR signaling, how do cells turn on
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SREBP2? One mechanism this can be accomplished through is the ER stress response
[126, 127]. Ju Youn Kim et. al. found that in hepatocytes, ER-stress induced caspase-2
expression controls the buildup of cholesterol and triglycerides by activating SREBPs in
the ER [127]. Stephen M. Colgan et. al. also showed ER stress-induced activation of
SREBP2 and subsequent cholesterol accumulation in cancer cell lines [126]. Now, only
one question remains. Does EGFR inhibition by EGFR TKIs induce ER stress?
Indeed, EGFR TKI treatment has been linked to the induction of ER stress response
and this is one of the reasons that patients experience diarrhea as a common side effect
of EGFR TKIs [128-130]. Shaocheng Hong et. al. found that EGFR TKIs triggered an ER
stress response through the activation of the RNA dependent protein kinase-like ER
kinase (PERK) and the induction of X-box binding protein 1 (XBP-1) signaling in intestinal
epithelial cells [129]. Hideki Terai et. al. found that erlotinib induced ER stress signaling
can promote the survival of EGFR TKI persister cells after exposure to erlotinib through
transcriptional adaptation via an epigenetic state change [130]. Taken together, these
studies highlight the possibility that, in our EGFR TKI DT model, EGFR TKI induced ER
stress is causing activation of SREBP2 and subsequent activation of cholesterol
synthesis, which is then accumulating in the mitochondria and blocking the release of
cytochrome c, thus allowing for survival even in the prescence of the EGFR TKI (Figure
46). EGFR TKI induced ER stress induction of SREBP2 would still have to be tested in
our model. However, the knowledge gained in this study could be useful in the future
development of therapies to overcome acquired resistance to EGFR TKIs, a major
problem in patients receiving EGFR TKIs.
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Figure 45: Ketoconazole Inhibits Cholesterol Synthesis and Restores Apoptosis
Upregulation of cholesterol is by induction of ER stress after EGFR TKI exposure. This
is inhibited by ketoconazole not allowing the cell to increase cholesterol levels within
the mitochondrial membrane. Without this survival mechanism, EGFR TKI exposure
leads to MOMP, release of cytochrome C, and apoptosis.
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